{
  "schema_version": "0.1.0",
  "case_id": "HR-ML030",
  "record_classification": {
    "synthetic": true,
    "banner": "SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD",
    "real_historical_name": true,
    "public_release_status": "draft"
  },
  "identity": {
    "person_id": "ML030",
    "display_name": "Barbara Jordan",
    "aliases": [
      "Barbara Charline Jordan"
    ],
    "sex": "female",
    "era": "Mid-Late 20th Century",
    "nationality": "American",
    "historical_dates": {
      "birth": {
        "preferred": {
          "iso": "1936-02-21",
          "display": "February 21, 1936",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1936",
              "display": "1936",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0009"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the Texas State Historical Association and the Texas State Cemetery."
          }
        ]
      },
      "death": {
        "preferred": {
          "iso": "1996-01-17",
          "display": "January 17, 1996",
          "precision": "day",
          "calendar": "gregorian"
        },
        "alternatives": [
          {
            "date": {
              "iso": "1996",
              "display": "1996",
              "precision": "year",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0009"
            ],
            "resolution_status": "preferred",
            "note": "Roster year agrees with the obituary."
          },
          {
            "date": {
              "iso": "1996-01-18",
              "display": "January 18, 1996",
              "precision": "day",
              "calendar": "gregorian"
            },
            "source_ids": [
              "SRC-0004"
            ],
            "resolution_status": "conflicting",
            "note": "One broadcaster's profile; the obituary, the House history, the Texas State Historical Association and the State Cemetery give January 17."
          }
        ]
      }
    },
    "synthetic_identity": {
      "mrn": "HR-ML030-SYN",
      "ssn": "000-30-6852",
      "date_of_birth": "1982-02-21",
      "name_policy": "real_historical_name",
      "fictional_facility": "St. Posthumous Health Center",
      "fictional_primary_clinician": "Evangeline Moss, MD",
      "fictional_consultant": {
        "name": "Kenji Watanabe, MD",
        "specialty": "Neurology (multiple sclerosis)"
      }
    }
  },
  "historical_timeline": [
    {
      "event_id": "EVT-0001",
      "date": {
        "iso": "1936-02-21",
        "display": "February 21, 1936",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Born in Houston, Texas.",
      "claim_ids": [
        "CLM-0001"
      ]
    },
    {
      "event_id": "EVT-0002",
      "date": {
        "iso": "1959",
        "display": "1959",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Law degree from Boston University.",
      "claim_ids": [
        "CLM-0001"
      ]
    },
    {
      "event_id": "EVT-0003",
      "date": {
        "iso": "1966",
        "display": "1966",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Elected to the Texas Senate.",
      "claim_ids": [
        "CLM-0002"
      ]
    },
    {
      "event_id": "EVT-0004",
      "date": {
        "iso": "1972-11",
        "display": "November 1972",
        "precision": "month",
        "calendar": "gregorian"
      },
      "summary": "Elected to the U.S. House of Representatives.",
      "claim_ids": [
        "CLM-0002"
      ]
    },
    {
      "event_id": "EVT-0005",
      "date": {
        "iso": "1974",
        "display": "1974",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "House Judiciary Committee impeachment hearings.",
      "claim_ids": [
        "CLM-0002"
      ]
    },
    {
      "event_id": "EVT-0006",
      "date": {
        "iso": "1976",
        "display": "1976",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Keynote address at the Democratic National Convention.",
      "claim_ids": [
        "CLM-0003"
      ]
    },
    {
      "event_id": "EVT-0007",
      "date": {
        "iso": "1978",
        "display": "1978",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Walking with a cane in her last House years, attributed at the time to a knee problem.",
      "claim_ids": [
        "CLM-0005"
      ]
    },
    {
      "event_id": "EVT-0008",
      "date": {
        "iso": "1979",
        "display": "1979",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Left the House; became a professor at the LBJ School of Public Affairs; multiple sclerosis diagnosed around this time, as later revealed.",
      "claim_ids": [
        "CLM-0004",
        "CLM-0006"
      ]
    },
    {
      "event_id": "EVT-0009",
      "date": {
        "iso": "1988",
        "display": "1988",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Spoke from a wheelchair at the Democratic National Convention.",
      "claim_ids": [
        "CLM-0007",
        "CLM-0008"
      ]
    },
    {
      "event_id": "EVT-0010",
      "date": {
        "iso": "1992",
        "display": "1992",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Convention keynote address from a wheelchair.",
      "claim_ids": [
        "CLM-0007"
      ]
    },
    {
      "event_id": "EVT-0011",
      "date": {
        "iso": "1994",
        "display": "1994",
        "precision": "year",
        "calendar": "gregorian"
      },
      "summary": "Presidential Medal of Freedom.",
      "claim_ids": [
        "CLM-0009"
      ]
    },
    {
      "event_id": "EVT-0012",
      "date": {
        "iso": "1996-01-17",
        "display": "January 17, 1996",
        "precision": "day",
        "calendar": "gregorian"
      },
      "summary": "Died in Austin at 59.",
      "claim_ids": [
        "CLM-0010"
      ]
    }
  ],
  "claims": [
    {
      "claim_id": "CLM-0001",
      "statement": "Barbara Jordan was born on February 21, 1936, in Houston, Texas, the youngest of three daughters, and grew up in Houston's Fifth Ward. She graduated magna cum laude from Texas Southern University in 1956 and earned a law degree from Boston University in 1959.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0008",
          "relationship": "supports",
          "locator": "birth date"
        },
        {
          "source_id": "SRC-0009",
          "relationship": "context",
          "locator": "roster birth year 1936"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0002",
      "statement": "In 1966 she was elected to the Texas Senate, the first Black state senator since 1883. In 1972 she was elected to the U.S. House of Representatives from Houston, the first Black woman from a Southern state to serve in Congress. As a member of the House Judiciary Committee during the 1974 impeachment hearings she said, \"My faith in the Constitution is whole, it is complete, it is total.\"",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0003",
      "statement": "In 1976 she gave the keynote address at the Democratic National Convention, the first woman and the first African American to do so.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors her public speaking in the modern social history.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0004",
      "statement": "She did not seek a fourth term and left the House in 1979, downplaying reports about her poor health and citing her \"internal compass.\" She became the Lyndon Baines Johnson Public Service Professor at the LBJ School of Public Affairs of the University of Texas at Austin, where she taught until the early 1990s.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "Anchors the modern episode in her work as a professor and public speaker in Austin, and the reports of poor health at the time she left Congress.",
      "source_links": [
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports",
          "locator": "widespread reports that failing health was the cause"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0005",
      "statement": "In her later years in the House she walked with a cane, which she attributed at the time to \"a bum knee\"; a disability-press account written after her death says this was the first adaptive equipment her multiple sclerosis required, and that she did not openly acknowledge the disease for years.",
      "evidence_grade": "D",
      "certainty": "probable",
      "clinical_interpretation": "The anchor for the modern episode, which begins about a year after she left the House, with a spastic gait and a cane. The account is a single posthumous article that reports her own public explanation at the time; it is graded probable.",
      "source_links": [
        {
          "source_id": "SRC-0006",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0006",
      "statement": "It was later revealed that she had been diagnosed with multiple sclerosis around the time she left Congress. The year of the diagnosis is not stated in the obituaries and reference works consulted.",
      "evidence_grade": "D",
      "certainty": "probable",
      "clinical_interpretation": "Anchors the modern problem of multiple sclerosis diagnosed elsewhere before the index visit. Its timing is uncertain (see CLM-0008).",
      "source_links": [
        {
          "source_id": "SRC-0007",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports",
          "locator": "later, it was announced that she had the disease"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0007",
      "statement": "She spoke from a wheelchair at the Democratic National Convention in 1988, and in 1992 she gave a second convention keynote address from a wheelchair, amid a lengthy battle with multiple sclerosis.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History after the modern episode; used only as context for the mobility planning.",
      "source_links": [
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports",
          "locator": "confined to a wheelchair by a degenerative disease"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0008",
      "statement": "Accounts differ on when her multiple sclerosis became public. A broadcaster's profile says it was announced after she left Congress; a disability-press article says her doctors made it public only after she nearly drowned in her pool during physical therapy, which it dates to 1994 (the Texas State Historical Association dates the near-drowning to 1988 and does not link it to the disease); a reference work says her obituaries explained much she had kept private, confirming the multiple sclerosis. Her obituaries reported that she had battled multiple sclerosis for several years and moved about in a wheelchair or with a walker.",
      "evidence_grade": "D",
      "certainty": "disputed",
      "clinical_interpretation": "Recorded as history; the modern episode does not depend on the date of disclosure, but respects her privacy about her health.",
      "source_links": [
        {
          "source_id": "SRC-0004",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0006",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "context",
          "locator": "near-drowning in 1988"
        },
        {
          "source_id": "SRC-0005",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0009",
      "statement": "She received the Presidential Medal of Freedom in 1994.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    },
    {
      "claim_id": "CLM-0010",
      "statement": "She died in Austin on January 17, 1996, at 59, of pneumonia as a complication of leukemia, and is buried in the Texas State Cemetery.",
      "evidence_grade": "D",
      "certainty": "confirmed",
      "clinical_interpretation": "History only, long after the modern episode; not used in it.",
      "source_links": [
        {
          "source_id": "SRC-0003",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0001",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0002",
          "relationship": "supports"
        },
        {
          "source_id": "SRC-0008",
          "relationship": "supports"
        }
      ],
      "release_status": "draft",
      "sensitive_content": false
    }
  ],
  "sources": [
    {
      "source_id": "SRC-0001",
      "title": "Jordan, Barbara Charline (Handbook of Texas Online)",
      "publisher": "Texas State Historical Association",
      "url": "https://www.tshaonline.org/handbook/entries/jordan-barbara-charline",
      "source_type": "biography",
      "published": null,
      "accessed": "2026-11-04",
      "rights_note": "Reference biography; facts used with citation."
    },
    {
      "source_id": "SRC-0002",
      "title": "JORDAN, Barbara Charline (Biographical Directory and Black Americans in Congress profile)",
      "publisher": "U.S. House of Representatives, History, Art & Archives",
      "url": "https://history.house.gov/People/Listing/J/JORDAN,-Barbara-Charline-(J000266)/",
      "source_type": "government",
      "published": null,
      "accessed": "2026-11-04",
      "rights_note": "Official House biography; facts used with citation."
    },
    {
      "source_id": "SRC-0003",
      "title": "Boyer EJ. Barbara Jordan, voice of conscience, dead at 59 (Los Angeles Times)",
      "publisher": "The Spokesman-Review",
      "url": "https://www.spokesman.com/stories/1996/jan/18/barbara-jordan-voice-of-conscience-dead-at-59-she",
      "source_type": "other",
      "published": "1996-01-18",
      "accessed": "2026-11-04",
      "rights_note": "Newspaper obituary quoting the head of the LBJ School and a University of Texas official; facts used with citation."
    },
    {
      "source_id": "SRC-0004",
      "title": "Barbara Jordan, 1936-1996: A Powerful Voice for Justice and Social Change (People in America)",
      "publisher": "Voice of America Learning English",
      "url": "https://learningenglish.voanews.com/amp/a-23-2007-04-21-voa2-83132962/127232.html",
      "source_type": "other",
      "published": "2007-04-21",
      "accessed": "2026-11-04",
      "rights_note": "Broadcaster's profile; used for the reports of poor health when she left Congress, the later announcement of the disease, and the 1988 wheelchair. It gives the death date as January 18, which other sources contradict."
    },
    {
      "source_id": "SRC-0005",
      "title": "Lunardini CA. Jordan, Barbara (Encyclopedia of African-American Culture and History)",
      "publisher": "Encyclopedia.com",
      "url": "https://encyclopedia.com/history/encyclopedias-almanacs-transcripts-and-maps/jordan-barbara",
      "source_type": "biography",
      "published": "1996",
      "accessed": "2026-11-04",
      "rights_note": "Reference entry; used for the wheelchair in 1992 and the obituaries confirming the disease she had kept private."
    },
    {
      "source_id": "SRC-0006",
      "title": "Cooper-Dowda R. Barbara Jordan: Hiding in Plain Sight While Working for 'The Common Good'",
      "publisher": "Ragged Edge Magazine",
      "url": "https://www.raggededgemagazine.com/extra/bjordan.htm",
      "source_type": "other",
      "published": "2002",
      "accessed": "2026-11-04",
      "rights_note": "Disability-press article written after her death; used only for the cane, her public explanation of it, and its account of the disclosure, with that account's date recorded as a conflict."
    },
    {
      "source_id": "SRC-0007",
      "title": "Barbara Jordan",
      "publisher": "Biography.com",
      "url": "https://www.biography.com/political-figures/barbara-jordan",
      "source_type": "biography",
      "published": null,
      "accessed": "2026-11-04",
      "rights_note": "Popular reference biography; used only for the later revelation that the diagnosis dated from around the time she left Congress."
    },
    {
      "source_id": "SRC-0008",
      "title": "Barbara Charline Jordan",
      "publisher": "Texas State Cemetery",
      "url": "https://cemetery.texas.gov/locate-a-plot/plotholder/barbara-charline-jordan",
      "source_type": "government",
      "published": null,
      "accessed": "2026-11-04",
      "rights_note": "Official cemetery biography; used for birth and death dates and burial."
    },
    {
      "source_id": "SRC-0009",
      "title": "HISTMED Master Roster v3",
      "publisher": "The Human Record project",
      "url": "https://humanrecord.example.org/internal/HISTMED_Master_Roster_v3.xlsx",
      "source_type": "other",
      "published": "2026-11-01",
      "accessed": "2026-11-04",
      "rights_note": "Internal source locator; inherited claims remain provisional until corroborated."
    }
  ],
  "synthetic_episode": {
    "calendar_frame": "modern_shifted",
    "index_date": "2026-03-02",
    "index_age": 44,
    "date_shift_policy": "HR-DATE-SHIFT-1",
    "teaching_objective": "Primary care, coordinated with a multiple sclerosis neurologist, for a 44-year-old professor and public speaker who walks with a cane and has multiple sclerosis diagnosed elsewhere: confirming and classifying the disease with MRI of the brain and spine under the 2017 McDonald criteria and the 2021 MAGNIMS-CMSC-NAIMS consensus, choosing a disease-modifying therapy by course and risk under the AAN 2018 guideline, the screening and vaccination it needs before the first dose (hepatitis B serology, immunoglobulins, liver tests, blood counts, varicella and measles immunity, tuberculosis, inactivated vaccines at least two weeks ahead), its monitoring afterwards, a re-baseline MRI, recognizing relapse and pseudo-relapse, symptom care for spasticity, bladder, fatigue and heat sensitivity, mobility equipment and fall prevention, a workplace accommodation that discloses only what she chooses, bone health, mood screening, and preventive care, respecting her wish to keep her diagnosis private.",
    "visit_schedule": [
      {
        "encounter_id": "ENC-001",
        "date": "2026-03-02",
        "purpose": "Establishing primary care for multiple sclerosis diagnosed elsewhere: walking, spasticity, bladder, fatigue and heat sensitivity, work, bone health, mood, and the work-up and screening before any disease-modifying therapy"
      },
      {
        "encounter_id": "ENC-002",
        "date": "2026-03-16",
        "purpose": "Two-week review with MRI of the brain and spine and the neurology (multiple sclerosis) consultation; vaccines before therapy"
      },
      {
        "encounter_id": "ENC-003",
        "date": "2026-04-20",
        "purpose": "Five-week review: second vaccine doses, baclofen titration, physical therapy and readiness for the first infusion"
      },
      {
        "encounter_id": "ENC-004",
        "date": "2026-06-29",
        "purpose": "Four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood"
      },
      {
        "encounter_id": "ENC-006",
        "date": "2026-08-17",
        "purpose": "Periodic adult preventive visit"
      },
      {
        "encounter_id": "ENC-005",
        "date": "2026-10-26",
        "purpose": "Eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work"
      }
    ]
  },
  "clinical": {
    "problems": [
      {
        "id": "PRB-001",
        "display": "Multiple sclerosis diagnosed elsewhere, by her account, with records of the original evaluation not available: slowly worsening walking over the past few years, leg stiffness, fatigue, urinary urgency and heat sensitivity; uses a cane; course to be classified after MRI of the brain and spine",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "G35.D",
            "display": "Multiple sclerosis, unspecified",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic presenting picture at intake, superseded by the classified diagnosis at the consultation; the cane and a diagnosis around the time she left Congress are from public accounts.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        },
        "clinical_status": "resolved",
        "verification_status": "confirmed",
        "problem_placement": "active",
        "abatement_date": "2026-03-16"
      },
      {
        "id": "PRB-002",
        "display": "Active primary progressive multiple sclerosis: gradual worsening of walking over more than a year without relapses, with brain lesions in periventricular, juxtacortical and infratentorial regions, three spinal cord lesions, and one gadolinium-enhancing lesion; fulfils the 2017 McDonald criteria for primary progressive disease; EDSS 6.0; synthetic modern detail linked to her publicly reported multiple sclerosis",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "G35.B1",
            "display": "Active primary progressive multiple sclerosis",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic course, MRI findings and disability score; the disease itself and her use of a cane are from public accounts.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "both_with_link",
        "recorded_date": "2026-03-16"
      },
      {
        "id": "PRB-003",
        "display": "Spastic gait from multiple sclerosis, walking with a cane, with two near-falls and no falls in the past year; at risk of falls",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "R26.89",
            "display": "Other abnormalities of gait and mobility",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic modern coding anchored to her documented cane.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active"
      },
      {
        "id": "PRB-004",
        "display": "Neurogenic bladder from multiple sclerosis: urgency and getting up twice at night, with a low post-void residual",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "N31.9",
            "display": "Neuromuscular dysfunction of bladder, unspecified",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic; common in multiple sclerosis. No public source describes her bladder.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active"
      },
      {
        "id": "PRB-005",
        "display": "Vitamin D deficiency",
        "status": "draft",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/icd-10-cm",
            "code": "E55.9",
            "display": "Vitamin D deficiency, unspecified",
            "version": "FY2026",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic laboratory finding at intake.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        },
        "clinical_status": "active",
        "verification_status": "confirmed",
        "problem_placement": "active"
      }
    ],
    "medications": [
      {
        "id": "MED-001",
        "display": "Cholecalciferol (vitamin D3) 2000 units (50 mcg) oral capsule, one capsule daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "804146",
            "display": "cholecalciferol 0.05 MG Oral Capsule",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One capsule daily"
        },
        "start_date": "2026-03-02",
        "indication_problem_ids": [
          "PRB-005"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vitamin D repletion for a deficient level.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "MED-002",
        "display": "Baclofen 5 mg oral tablet, one tablet three times a day, to be increased to 10 mg three times a day once tolerated",
        "status": "completed",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "430902",
            "display": "baclofen 5 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 8,
          "period_unit": "h",
          "text": "One tablet three times a day"
        },
        "start_date": "2026-03-16",
        "end_date": "2026-04-20",
        "indication_problem_ids": [
          "PRB-002",
          "PRB-003"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic first-line treatment for leg spasticity, started at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "MED-003",
        "display": "Baclofen 10 mg oral tablet, one tablet three times a day",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "197391",
            "display": "baclofen 10 MG Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 8,
          "period_unit": "h",
          "text": "One tablet three times a day"
        },
        "start_date": "2026-04-20",
        "indication_problem_ids": [
          "PRB-002",
          "PRB-003"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic baclofen at the target dose after titration.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "MED-004",
        "display": "Mirabegron 25 mg extended-release oral tablet, one tablet daily",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1300791",
            "display": "24 HR mirabegron 25 MG Extended Release Oral Tablet",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 1,
          "unit": "1"
        },
        "route": "oral",
        "frequency": {
          "period": 1,
          "period_unit": "d",
          "text": "One tablet daily"
        },
        "start_date": "2026-03-16",
        "indication_problem_ids": [
          "PRB-004"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic treatment for urinary urgency with a low post-void residual, chosen over an anticholinergic to avoid effects on memory and concentration.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "MED-005",
        "display": "Ocrelizumab 300 mg intravenous infusion on day 1 and day 15, then 600 mg every 6 months, after methylprednisolone 100 mg intravenously, an antihistamine and acetaminophen, in the infusion center",
        "status": "active",
        "coding": [
          {
            "system": "http://www.nlm.nih.gov/research/umls/rxnorm",
            "code": "1876380",
            "display": "10 ML ocrelizumab 30 MG/ML Injection",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "dose": {
          "value": 300,
          "unit": "mg"
        },
        "route": "intravenous",
        "frequency": {
          "period": 2,
          "period_unit": "wk",
          "text": "300 mg on day 1 and day 15 (given), then 600 mg every 6 months"
        },
        "start_date": "2026-05-04",
        "indication_problem_ids": [
          "PRB-002"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic disease-modifying therapy for active primary progressive multiple sclerosis, chosen at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "allergies": [
      {
        "id": "ALG-001",
        "display": "No known allergy",
        "status": "active",
        "assertion": "no_known_allergy",
        "substance": {
          "system": "http://snomed.info/sct",
          "code": "716186003",
          "display": "No known allergy"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic allergy assertion for EHR completeness; not a historical assertion.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "observations": [
      {
        "id": "OBS-WBC-V1",
        "display": "Leukocytes [#/volume] in Blood by Automated count",
        "label": "White cells",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 6.4,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 4.0,
          "high": 11.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6690-2",
            "display": "Leukocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count with absolute lymphocytes, a baseline before any disease-modifying therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-LYMPH-V1",
        "display": "Lymphocytes [#/volume] in Blood by Automated count",
        "label": "Lymphocytes (absolute)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 1.9,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 1.0,
          "high": 4.8
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "731-0",
            "display": "Lymphocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count with absolute lymphocytes, a baseline before any disease-modifying therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-HGB-V1",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 13.2,
        "unit": "g/dL",
        "reference_range": {
          "low": 12.0,
          "high": 15.5
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count with absolute lymphocytes, a baseline before any disease-modifying therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PLT-V1",
        "display": "Platelets [#/volume] in Blood by Automated count",
        "label": "Platelets",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 262,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 150,
          "high": 400
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "777-3",
            "display": "Platelets [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count with absolute lymphocytes, a baseline before any disease-modifying therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V1",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 0.78,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.59,
          "high": 1.04
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic creatinine; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V1",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR (CKD-EPI 2021)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 96,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic eGFR (CKD-EPI 2021); normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V1",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 18,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic liver tests; baseline before any disease-modifying therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V1",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 20,
        "unit": "U/L",
        "reference_range": {
          "low": 10,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic liver tests; baseline before any disease-modifying therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALP-V1",
        "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "Alkaline phosphatase",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 72,
        "unit": "U/L",
        "reference_range": {
          "low": 35,
          "high": 105
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6768-6",
            "display": "Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic liver tests; baseline before any disease-modifying therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-BILI-V1",
        "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
        "label": "Total bilirubin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 0.5,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.2,
          "high": 1.2
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1975-2",
            "display": "Bilirubin.total [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic liver tests; baseline before any disease-modifying therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-TSH-V1",
        "display": "Thyrotropin [Units/volume] in Serum or Plasma",
        "label": "TSH",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 1.8,
        "unit": "m[IU]/L",
        "reference_range": {
          "low": 0.4,
          "high": 4.5
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "3016-3",
            "display": "Thyrotropin [Units/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic TSH, excluding a thyroid cause of fatigue; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-B12-V1",
        "display": "Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma",
        "label": "Vitamin B12",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 520,
        "unit": "pg/mL",
        "reference_range": {
          "low": 232,
          "high": 1245
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2132-9",
            "display": "Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vitamin B12, excluding a B12 cause of spastic gait and sensory loss; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-VITD-V1",
        "display": "25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma",
        "label": "25-hydroxyvitamin D",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 17,
        "unit": "ng/mL",
        "reference_range": {
          "low": 30,
          "high": 100
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "62292-8",
            "display": "25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic 25-hydroxyvitamin D; deficient, common with multiple sclerosis and limited time outdoors.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-IGG-V1",
        "display": "IgG [Mass/volume] in Serum or Plasma",
        "label": "IgG",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 1080,
        "unit": "mg/dL",
        "reference_range": {
          "low": 700,
          "high": 1600
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2465-3",
            "display": "IgG [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic quantitative immunoglobulins; baseline before a B-cell therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-IGM-V1",
        "display": "IgM [Mass/volume] in Serum or Plasma",
        "label": "IgM",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 110,
        "unit": "mg/dL",
        "reference_range": {
          "low": 40,
          "high": 230
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2472-9",
            "display": "IgM [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic quantitative immunoglobulins; baseline before a B-cell therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-IGA-V1",
        "display": "IgA [Mass/volume] in Serum or Plasma",
        "label": "IgA",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 210,
        "unit": "mg/dL",
        "reference_range": {
          "low": 70,
          "high": 400
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2458-8",
            "display": "IgA [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic quantitative immunoglobulins; baseline before a B-cell therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-JCV-V1",
        "display": "JC virus Ab Index in Serum or Plasma by Immunoassay",
        "label": "JC virus antibody index",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-03-02",
        "value": 0.14,
        "unit": "{index}",
        "reference_range": {
          "high": 0.2,
          "text": "Below 0.20 negative; 0.20 to 0.40 indeterminate; above 0.40 positive"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "100977-8",
            "display": "JC virus Ab Index in Serum or Plasma by Immunoassay",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic JC virus antibody index; negative, recorded to inform any later therapy choice.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V1",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-03-02",
        "value": 6,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic depression screen; mild symptoms, mostly fatigue and sleep items. Not a claim about her real mood.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-WBC-V4",
        "display": "Leukocytes [#/volume] in Blood by Automated count",
        "label": "White cells",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-29",
        "value": 5.9,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 4.0,
          "high": 11.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6690-2",
            "display": "Leukocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count after the first ocrelizumab doses; lymphocytes normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-LYMPH-V4",
        "display": "Lymphocytes [#/volume] in Blood by Automated count",
        "label": "Lymphocytes (absolute)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-29",
        "value": 1.4,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 1.0,
          "high": 4.8
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "731-0",
            "display": "Lymphocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count after the first ocrelizumab doses; lymphocytes normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-HGB-V4",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-29",
        "value": 13.4,
        "unit": "g/dL",
        "reference_range": {
          "low": 12.0,
          "high": 15.5
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count after the first ocrelizumab doses; lymphocytes normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PLT-V4",
        "display": "Platelets [#/volume] in Blood by Automated count",
        "label": "Platelets",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-29",
        "value": 248,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 150,
          "high": 400
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "777-3",
            "display": "Platelets [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count after the first ocrelizumab doses; lymphocytes normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CD19-V4",
        "display": "CD19 cells [#/volume] in Blood",
        "label": "CD19 B cells (absolute)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-29",
        "value": 3,
        "unit": "/uL",
        "reference_range": {
          "low": 107,
          "high": 698,
          "text": "Expected to be depleted after an anti-CD20 therapy"
        },
        "interpretation": "L",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "8116-6",
            "display": "CD19 cells [#/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic CD19 count: B cells depleted, the expected effect of ocrelizumab.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V4",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-29",
        "value": 20,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic ALT after the first ocrelizumab doses; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-VITD-V4",
        "display": "25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma",
        "label": "25-hydroxyvitamin D",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-06-29",
        "value": 34,
        "unit": "ng/mL",
        "reference_range": {
          "low": 30,
          "high": 100
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "62292-8",
            "display": "25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic 25-hydroxyvitamin D after four months of vitamin D3; replete.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ9-V4",
        "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
        "label": "PHQ-9",
        "status": "final",
        "effective_date": "2026-06-29",
        "value": 3,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "44261-6",
            "display": "Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic PHQ-9; minimal symptoms.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-A1C-V6",
        "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
        "label": "Hemoglobin A1c",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-17",
        "value": 5.4,
        "unit": "%",
        "reference_range": {
          "high": 5.6,
          "text": "Below 5.7% is normal; 5.7 to 6.4% prediabetes"
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "4548-4",
            "display": "Hemoglobin A1c/Hemoglobin.total in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic A1c in diabetes screening; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CHOL-V6",
        "display": "Cholesterol [Mass/volume] in Serum or Plasma",
        "label": "Total cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-17",
        "value": 186,
        "unit": "mg/dL",
        "reference_range": {
          "high": 199
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2093-3",
            "display": "Cholesterol [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel; estimated ten-year cardiovascular risk low.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-LDL-V6",
        "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
        "label": "LDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-17",
        "value": 110,
        "unit": "mg/dL",
        "reference_range": {
          "high": 129
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "13457-7",
            "display": "Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel; estimated ten-year cardiovascular risk low.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-HDL-V6",
        "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
        "label": "HDL cholesterol",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-17",
        "value": 56,
        "unit": "mg/dL",
        "reference_range": {
          "low": 50
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2085-9",
            "display": "Cholesterol in HDL [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel; estimated ten-year cardiovascular risk low.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-TG-V6",
        "display": "Triglyceride [Mass/volume] in Serum or Plasma",
        "label": "Triglycerides",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-08-17",
        "value": 98,
        "unit": "mg/dL",
        "reference_range": {
          "high": 149
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2571-8",
            "display": "Triglyceride [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic lipid panel; estimated ten-year cardiovascular risk low.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-WBC-V5",
        "display": "Leukocytes [#/volume] in Blood by Automated count",
        "label": "White cells",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 6.1,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 4.0,
          "high": 11.0
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "6690-2",
            "display": "Leukocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count before the next ocrelizumab dose; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-LYMPH-V5",
        "display": "Lymphocytes [#/volume] in Blood by Automated count",
        "label": "Lymphocytes (absolute)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 1.5,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 1.0,
          "high": 4.8
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "731-0",
            "display": "Lymphocytes [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count before the next ocrelizumab dose; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-HGB-V5",
        "display": "Hemoglobin [Mass/volume] in Blood",
        "label": "Hemoglobin",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 13.5,
        "unit": "g/dL",
        "reference_range": {
          "low": 12.0,
          "high": 15.5
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "718-7",
            "display": "Hemoglobin [Mass/volume] in Blood",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count before the next ocrelizumab dose; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PLT-V5",
        "display": "Platelets [#/volume] in Blood by Automated count",
        "label": "Platelets",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 255,
        "unit": "10*3/uL",
        "reference_range": {
          "low": 150,
          "high": 400
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "777-3",
            "display": "Platelets [#/volume] in Blood by Automated count",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic blood count before the next ocrelizumab dose; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-IGG-V5",
        "display": "IgG [Mass/volume] in Serum or Plasma",
        "label": "IgG",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 1010,
        "unit": "mg/dL",
        "reference_range": {
          "low": 700,
          "high": 1600
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2465-3",
            "display": "IgG [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic immunoglobulins on ocrelizumab; IgM lower than at baseline but normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-IGM-V5",
        "display": "IgM [Mass/volume] in Serum or Plasma",
        "label": "IgM",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 72,
        "unit": "mg/dL",
        "reference_range": {
          "low": 40,
          "high": 230
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2472-9",
            "display": "IgM [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic immunoglobulins on ocrelizumab; IgM lower than at baseline but normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-CR-V5",
        "display": "Creatinine [Mass/volume] in Serum or Plasma",
        "label": "Creatinine",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 0.8,
        "unit": "mg/dL",
        "reference_range": {
          "low": 0.59,
          "high": 1.04
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "2160-0",
            "display": "Creatinine [Mass/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic creatinine; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-EGFR-V5",
        "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
        "label": "eGFR (CKD-EPI 2021)",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 93,
        "unit": "mL/min/{1.73_m2}",
        "reference_range": {
          "low": 60
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "98979-8",
            "display": "Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic eGFR (CKD-EPI 2021).",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-ALT-V5",
        "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "ALT",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 19,
        "unit": "U/L",
        "reference_range": {
          "low": 7,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1742-6",
            "display": "Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic ALT; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-AST-V5",
        "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
        "label": "AST",
        "status": "final",
        "category": "laboratory",
        "effective_date": "2026-10-26",
        "value": 21,
        "unit": "U/L",
        "reference_range": {
          "low": 10,
          "high": 35
        },
        "interpretation": "N",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "1920-8",
            "display": "Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic AST; normal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "OBS-PHQ2-V6",
        "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
        "label": "PHQ-2",
        "status": "final",
        "effective_date": "2026-08-17",
        "value": 0,
        "unit": "{score}",
        "coding": [
          {
            "system": "http://loinc.org",
            "code": "55758-7",
            "display": "Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]",
            "version": "2.81",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic depression screen; negative. Not a claim about her real mood.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "procedures": [
      {
        "id": "PROC-001",
        "display": "Bladder scan for post-void residual volume",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "169251004",
            "display": "Ultrasonography of urinary bladder",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-03-02",
          "end": "2026-03-02"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic post-void residual of 40 mL (reported in the note text).",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-002",
        "display": "MRI of the brain with and without gadolinium (3D T2-FLAIR, T2, and T1 before and after contrast)",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "816077007",
            "display": "MRI of brain",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-03-16",
          "end": "2026-03-16"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic diagnostic MRI to the MAGNIMS-CMSC-NAIMS protocol; findings in the note text.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-003",
        "display": "MRI of the cervical and thoracic spine with and without gadolinium",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "702607002",
            "display": "MRI of cervical and thoracic spine",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-03-16",
          "end": "2026-03-16"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic spinal cord MRI at diagnosis; three cord lesions, no compression (reported in the note text).",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-004",
        "display": "Ocrelizumab 300 mg intravenous infusion (first half-dose) after premedication, with observation for at least one hour afterwards",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "14152002",
            "display": "Intravenous infusion",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-05-04",
          "end": "2026-05-04"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic first infusion; mild throat irritation that settled with slowing of the infusion (reported in the note text).",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-005",
        "display": "Ocrelizumab 300 mg intravenous infusion (second half-dose) after premedication, with observation for at least one hour afterwards",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "14152002",
            "display": "Intravenous infusion",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-05-18",
          "end": "2026-05-18"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic second infusion; no reaction.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-006",
        "display": "MRI of the brain without gadolinium (re-baseline on therapy)",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "816077007",
            "display": "MRI of brain",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-10-26",
          "end": "2026-10-26"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic re-baseline MRI five to six months after starting therapy; no new or enlarging lesions (reported in the note text).",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-007",
        "display": "Dual-energy X-ray absorptiometry (DXA) of the lumbar spine and hip",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "312681000",
            "display": "Bone density scan",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-08-17",
          "end": "2026-08-17"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bone density scan for reduced mobility and earlier steroid courses; Z-scores within the expected range for age (reported in the note text).",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-008",
        "display": "Advance care planning conversation, about 20 minutes",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "713603004",
            "display": "Advance care planning",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-08-17",
          "end": "2026-08-17"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic voluntary advance care planning; records only her own general preferences.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "PROC-009",
        "display": "Screening mammogram, both breasts",
        "status": "completed",
        "coding": [
          {
            "system": "http://snomed.info/sct",
            "code": "24623002",
            "display": "Screening mammography",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "period": {
          "start": "2026-08-31",
          "end": "2026-08-31"
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic screening mammogram two weeks after the preventive visit; no abnormality (reported in the note text).",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "immunizations": [
      {
        "id": "IMM-001",
        "display": "Pneumococcal conjugate vaccine PCV20",
        "status": "completed",
        "date": "2026-03-16",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "216",
            "display": "Pneumococcal conjugate PCV20, polysaccharide CRM197 conjugate, adjuvant, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic single dose for an adult about to start immunosuppressive therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "IMM-002",
        "display": "Recombinant zoster vaccine, dose 1 of 2",
        "status": "completed",
        "date": "2026-03-16",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "187",
            "display": "zoster recombinant",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic first dose for an adult who will be immunosuppressed.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "IMM-003",
        "display": "Tetanus, diphtheria, and acellular pertussis vaccine (Tdap)",
        "status": "completed",
        "date": "2026-03-16",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "115",
            "display": "Tdap",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic Tdap; no booster recorded within ten years.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "IMM-004",
        "display": "Hepatitis B vaccine (HepB-CpG), dose 1 of 2",
        "status": "completed",
        "date": "2026-03-16",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "189",
            "display": "HepB-CpG",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic hepatitis B vaccination for a non-immune adult before a B-cell therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "IMM-005",
        "display": "Hepatitis B vaccine (HepB-CpG), dose 2 of 2",
        "status": "completed",
        "date": "2026-04-20",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "189",
            "display": "HepB-CpG",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic second dose, at least four weeks after the first.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "IMM-006",
        "display": "Recombinant zoster vaccine, dose 2 of 2",
        "status": "completed",
        "date": "2026-04-20",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "187",
            "display": "zoster recombinant",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic second dose on the shortened schedule for someone about to be immunosuppressed.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "IMM-007",
        "display": "Influenza vaccine, inactivated, this season",
        "status": "completed",
        "date": "2026-10-26",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "140",
            "display": "Influenza, split virus, trivalent, PF",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seasonal influenza vaccination, two weeks before the next infusion.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "IMM-008",
        "display": "COVID-19 vaccine, mRNA, this season",
        "status": "completed",
        "date": "2026-10-26",
        "coding": [
          {
            "system": "http://hl7.org/fhir/sid/cvx",
            "code": "309",
            "display": "COVID-19, mRNA, LNP-S, PF, tris-sucrose, 30 mcg/0.3 mL",
            "validation_status": "validated",
            "validated_on": "2026-11-04"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic seasonal COVID-19 vaccination for an adult on a B-cell therapy.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "family_history": [],
    "past_medical_history": [
      {
        "id": "PMH-001",
        "display": "Walking difficulty needing a cane in her last years in the House, attributed publicly at the time to a knee problem",
        "historical_date": {
          "iso": "1978",
          "display": "1978",
          "precision": "year",
          "calendar": "gregorian"
        },
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "PMH-002",
        "display": "Multiple sclerosis diagnosed around the time she left Congress, as later revealed; records of that evaluation are not available to this clinic",
        "historical_date": {
          "iso": "1979",
          "display": "1979",
          "precision": "year",
          "calendar": "gregorian"
        },
        "provenance": {
          "evidence_grade": "D",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": null,
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "encounters": [
      {
        "id": "ENC-001",
        "display": "Establishing primary care for multiple sclerosis diagnosed elsewhere: walking, spasticity, bladder, fatigue and heat sensitivity, work, bone health, mood, and the work-up and screening before any disease-modifying therapy",
        "status": "finished",
        "date": "2026-03-02",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "ENC-002",
        "display": "Two-week review with MRI of the brain and spine and the neurology (multiple sclerosis) consultation; vaccines before therapy",
        "status": "finished",
        "date": "2026-03-16",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-04"
        },
        "documentation": {
          "chief_complaint": "Two-week review with MRI of the brain and spine, seen the same day by multiple sclerosis neurology",
          "hpi": {
            "narrative": "Ms. Jordan returns two weeks after her first visit, after MRI of the brain and spine this morning, and is seen by Dr. Watanabe of multiple sclerosis neurology on the same day. Her walking is unchanged: she uses her cane on campus and rests after about 100 meters. She has had no new symptoms and no symptom that came on over days. Her legs are stiff in the mornings. She still gets up twice a night to pass urine and sometimes has to hurry. She has started vitamin D3. The records of her original evaluation have not arrived. She asked about treatments that might slow the disease and how often she would need to be away from work for them.",
            "elements": [
              {
                "label": "Walking",
                "value": "Cane on campus; rests after about 100 meters; unchanged"
              },
              {
                "label": "New symptoms",
                "value": "None"
              },
              {
                "label": "Bladder",
                "value": "Urgency; up twice a night"
              },
              {
                "label": "Imaging",
                "value": "MRI of the brain and cervical and thoracic spine with gadolinium this morning"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Tires by mid-afternoon; no fever"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No blurred or double vision"
            },
            {
              "system": "Genitourinary",
              "status": "positive",
              "finding": "Urgency and nocturia twice; no burning"
            },
            {
              "system": "Musculoskeletal",
              "status": "positive",
              "finding": "Leg stiffness in the mornings"
            },
            {
              "system": "Neurological",
              "status": "positive",
              "finding": "Slowly worsening walking; no new numbness or weakness"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood steady"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; blood pressure 122/76, pulse 74"
            },
            {
              "system": "Neurological",
              "finding": "Spastic paraparetic gait with a cane in the right hand; hip flexor strength 4 out of 5 on both sides; modified Ashworth 2 in both legs; brisk leg reflexes with extensor plantar responses; reduced vibration sense at the toes; EDSS 6.0; timed 25-foot walk 11.0 seconds"
            },
            {
              "system": "Eyes",
              "finding": "Visual acuity 20/20 in each eye; no relative afferent pupillary defect"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Active primary progressive multiple sclerosis",
              "assessment": "MRI brain: fourteen T2 lesions, periventricular, juxtacortical and infratentorial (pons and left middle cerebellar peduncle), one enhancing right periventricular lesion. MRI spine: three cord lesions at C3, C5 and T6, each less than two segments long, with no compression. With more than a year of gradually worsening walking and no relapses, these meet the 2017 McDonald criteria for primary progressive multiple sclerosis (brain lesions in characteristic regions and two or more cord lesions), and the enhancing lesion makes it active. B12, TSH and HIV results exclude the main mimics. Dr. Watanabe advises ocrelizumab. Screening before therapy: hepatitis B surface antigen, core antibody and surface antibody all negative (not infected, not immune); immunoglobulins, liver tests and blood count normal; varicella IgG and measles, mumps and rubella IgG positive; tuberculosis blood test, HIV and hepatitis C negative; JC virus antibody index 0.14, negative",
              "plan": [
                "Vaccines today: PCV20, recombinant zoster dose 1, Tdap and hepatitis B dose 1; second zoster and hepatitis B doses in about five weeks",
                "First ocrelizumab half-dose at least two weeks after the last vaccine",
                "Reproductive plans discussed privately with Dr. Watanabe and recorded in the confidential part of the chart"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Spastic gait and fall risk",
              "assessment": "Spasticity limits her walking and stiffens her mornings; no falls",
              "plan": [
                "Start baclofen 5 mg three times a day, increasing to 10 mg three times a day once tolerated",
                "Physical therapy evaluation requested at intake; awaiting a first appointment"
              ]
            },
            {
              "problem_id": "PRB-004",
              "display": "Neurogenic bladder",
              "assessment": "Urgency with a low post-void residual of 40 mL at intake, so a bladder-relaxing medicine is safe",
              "plan": [
                "Start mirabegron 25 mg daily rather than an anticholinergic, to avoid effects on concentration; blood pressure at each visit",
                "Continue timed voiding and fluids earlier in the day"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "examination",
              "measure": "New or worsening symptoms (relapse, pseudo-relapse with heat or infection)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No new symptoms; relapse and pseudo-relapse plan explained with a written card",
              "guideline_ids": [
                "GL-AAN-DMT-2018",
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "examination",
              "measure": "Disability: EDSS and timed 25-foot walk",
              "cadence": "Every visit, and at least every 6 months",
              "status": "completed_today",
              "detail": "EDSS 6.0; timed 25-foot walk 11.0 seconds",
              "guideline_ids": [
                "GL-AAN-DMT-2018"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Brain MRI",
              "cadence": "At diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadolinium",
              "status": "completed_today",
              "detail": "Diagnostic MRI with gadolinium: fourteen T2 lesions in characteristic regions; one enhancing lesion",
              "guideline_ids": [
                "GL-MAGNIMS-2021",
                "GL-MCDONALD-2017"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Spinal cord MRI",
              "cadence": "At diagnosis; later only for new spinal symptoms or diagnostic doubt",
              "status": "completed_today",
              "detail": "Three cord lesions; no compression",
              "guideline_ids": [
                "GL-MAGNIMS-2021",
                "GL-MCDONALD-2017"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Hepatitis B surface antigen, core antibody and surface antibody",
              "cadence": "Before the first dose",
              "status": "up_to_date",
              "detail": "All negative at intake: not infected, not immune; vaccination started today",
              "guideline_ids": [
                "GL-OCR-LABEL",
                "GL-AAN-VAX-2019"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Quantitative immunoglobulins",
              "cadence": "Before the first dose, then before each dose",
              "status": "up_to_date",
              "detail": "IgG 1080, IgM 110, IgA 210 mg/dL at intake",
              "guideline_ids": [
                "GL-OCR-LABEL"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Blood count with absolute lymphocytes",
              "cadence": "Before the first dose, then before each dose",
              "status": "up_to_date",
              "detail": "White cells 6.4, lymphocytes 1.9 at intake",
              "guideline_ids": [
                "GL-OCR-LABEL",
                "GL-AAN-DMT-2018"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Liver tests",
              "cadence": "Before the first dose, then with symptoms and before each dose",
              "status": "up_to_date",
              "detail": "Normal at intake",
              "guideline_ids": [
                "GL-OCR-LABEL"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Varicella and measles immunity, tuberculosis blood test, HIV, hepatitis C, JC virus antibody",
              "cadence": "Before the first dose",
              "status": "up_to_date",
              "detail": "Varicella and measles immune; tuberculosis blood test, HIV and hepatitis C negative; JC virus antibody index 0.14",
              "guideline_ids": [
                "GL-AAN-VAX-2019",
                "GL-AAN-DMT-2018"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Vaccines before therapy (PCV20, recombinant zoster x2, Tdap, hepatitis B x2)",
              "cadence": "Inactivated at least 2 weeks and live at least 4 weeks before the first dose",
              "status": "completed_today",
              "detail": "PCV20, zoster dose 1, Tdap and hepatitis B dose 1 today; no live vaccine needed",
              "guideline_ids": [
                "GL-AAN-VAX-2019",
                "GL-CDC-IMZ-2026",
                "GL-OCR-LABEL"
              ]
            },
            {
              "domain": "examination",
              "measure": "Spasticity (modified Ashworth) and baclofen tolerance",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Modified Ashworth 2 in both legs; baclofen started",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "examination",
              "measure": "Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Urgency and nocturia twice; post-void residual 40 mL at intake; mirabegron started; blood pressure 122/76",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "referral",
              "measure": "Falls, walking aids and physical therapy",
              "cadence": "Every visit",
              "status": "ordered",
              "detail": "No falls; physical therapy evaluation requested at intake, first appointment awaited",
              "guideline_ids": [
                "GL-NICE-MS-2022",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Fatigue and heat sensitivity",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Tires by mid-afternoon; pacing and cooling advice given",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "25-hydroxyvitamin D",
              "cadence": "At baseline, 8 to 12 weeks after repletion, then yearly",
              "status": "up_to_date",
              "detail": "17 ng/mL at intake; vitamin D3 started at intake",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Depression screen (PHQ-9)",
              "cadence": "At intake, then every 6 months and with any change",
              "status": "up_to_date",
              "detail": "PHQ-9 6 at intake, mostly fatigue and sleep items",
              "guideline_ids": [
                "GL-USPSTF-DEP-2023",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Workplace accommodation",
              "cadence": "At intake and with any change",
              "status": "completed_today",
              "detail": "Letter describing her functional needs, without the diagnosis, given to her to send as she chooses",
              "guideline_ids": [
                "GL-JAN-MS",
                "GL-ADA"
              ]
            },
            {
              "domain": "referral",
              "measure": "Multiple sclerosis neurology review",
              "cadence": "At diagnosis, then every 6 months on therapy",
              "status": "completed_today",
              "detail": "Seen by Dr. Watanabe today",
              "guideline_ids": [
                "GL-AAN-DMT-2018"
              ]
            }
          ],
          "follow_up": "Review in five weeks for the second vaccine doses and baclofen titration; first ocrelizumab infusion to be booked at least two weeks after that visit. Same-day call for new or worsening symptoms lasting more than 24 hours",
          "guideline_ids": [
            "GL-AAN-DMT-2018",
            "GL-MCDONALD-2017",
            "GL-MAGNIMS-2021",
            "GL-AAN-VAX-2019",
            "GL-OCR-LABEL",
            "GL-NICE-MS-2022",
            "GL-CDC-IMZ-2026",
            "GL-JAN-MS",
            "GL-ADA"
          ]
        }
      },
      {
        "id": "ENC-003",
        "display": "Five-week review: second vaccine doses, baclofen titration, physical therapy and readiness for the first infusion",
        "status": "finished",
        "date": "2026-04-20",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-04"
        },
        "documentation": {
          "chief_complaint": "Five-week review: second vaccine doses, baclofen titration, physical therapy, and readiness for the first infusion",
          "hpi": {
            "narrative": "Ms. Jordan returns five weeks after the consultation. Baclofen 5 mg three times a day made her drowsy for the first week; this has passed, and her mornings are less stiff. Mirabegron has helped: she now gets up once most nights. She had a sore arm for a day after the vaccines and no other reaction. She has had no new symptoms and no infection. The physical therapy evaluation requested at intake has not happened: the clinic's therapist with experience in multiple sclerosis has a waiting list, and she has not yet been offered a date. Her employer has agreed to the accommodations she asked for. She would like the infusions on days without teaching.",
            "elements": [
              {
                "label": "Baclofen",
                "value": "Drowsy the first week, now settled; stiffness better"
              },
              {
                "label": "Bladder",
                "value": "Up once most nights on mirabegron"
              },
              {
                "label": "Physical therapy",
                "value": "Not yet seen; waiting list"
              },
              {
                "label": "Work",
                "value": "Accommodations agreed"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "No fever or infection"
            },
            {
              "system": "Genitourinary",
              "status": "negative",
              "finding": "Urgency better; no burning"
            },
            {
              "system": "Musculoskeletal",
              "status": "positive",
              "finding": "Mild morning stiffness"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No new numbness, weakness or visual change"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; blood pressure 120/76, pulse 72; temperature 36.6 °C"
            },
            {
              "system": "Neurological",
              "finding": "Gait unchanged with a cane; modified Ashworth 1+ in both legs; hip flexor strength 4 out of 5, unchanged with baclofen"
            },
            {
              "system": "Skin",
              "finding": "No rash; vaccine sites healed"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Active primary progressive multiple sclerosis",
              "assessment": "Stable, with no infection; ready for ocrelizumab after today's vaccines",
              "plan": [
                "Recombinant zoster dose 2 and hepatitis B dose 2 today",
                "First ocrelizumab half-dose in two weeks and the second two weeks later, on days without teaching, with premedication and at least one hour of observation",
                "Infusion center to confirm no active infection before each dose"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Spastic gait and fall risk",
              "assessment": "Baclofen tolerated with less stiffness and no added weakness. The physical therapy evaluation is overdue",
              "plan": [
                "Increase baclofen to 10 mg three times a day",
                "Clinic to ask the physical therapy service today for the first available date, with a second provider if none is offered within three weeks",
                "Daily stretching and her home exercises meanwhile"
              ]
            },
            {
              "problem_id": "PRB-004",
              "display": "Neurogenic bladder",
              "assessment": "Better on mirabegron; blood pressure unchanged",
              "plan": [
                "Continue mirabegron 25 mg daily"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "examination",
              "measure": "New or worsening symptoms (relapse, pseudo-relapse with heat or infection)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No new symptoms",
              "guideline_ids": [
                "GL-AAN-DMT-2018",
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "examination",
              "measure": "Disability: EDSS and timed 25-foot walk",
              "cadence": "Every visit, and at least every 6 months",
              "status": "up_to_date",
              "detail": "EDSS 6.0 five weeks ago; gait unchanged today",
              "guideline_ids": [
                "GL-AAN-DMT-2018"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Brain MRI",
              "cadence": "At diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadolinium",
              "status": "up_to_date",
              "detail": "Diagnostic MRI five weeks ago; re-baseline due three to six months after the first dose",
              "guideline_ids": [
                "GL-MAGNIMS-2021"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Vaccines before therapy (PCV20, recombinant zoster x2, Tdap, hepatitis B x2)",
              "cadence": "Inactivated at least 2 weeks and live at least 4 weeks before the first dose",
              "status": "completed_today",
              "detail": "Zoster dose 2 and hepatitis B dose 2 today; series complete; first infusion two weeks from today",
              "guideline_ids": [
                "GL-AAN-VAX-2019",
                "GL-CDC-IMZ-2026",
                "GL-OCR-LABEL"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Infusion reactions and infections",
              "cadence": "Each infusion, and every visit",
              "status": "completed_today",
              "detail": "No infection today; premedication and observation planned",
              "guideline_ids": [
                "GL-OCR-LABEL"
              ]
            },
            {
              "domain": "examination",
              "measure": "Spasticity (modified Ashworth) and baclofen tolerance",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Modified Ashworth 1+; baclofen increased to 10 mg three times a day",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "examination",
              "measure": "Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Nocturia once; blood pressure 120/76 on mirabegron",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "referral",
              "measure": "Falls, walking aids and physical therapy",
              "cadence": "Every visit",
              "status": "deferred",
              "detail": "Missed: the physical therapy evaluation requested at intake has not happened because of a waiting list. No harm so far: no falls and her gait is unchanged. Corrective action: the clinic asked the service today for the first available date, with a second provider if none is offered within three weeks; daily stretching and home exercises meanwhile",
              "guideline_ids": [
                "GL-NICE-MS-2022",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Workplace accommodation",
              "cadence": "At intake and with any change",
              "status": "completed_today",
              "detail": "Accommodations agreed by her employer",
              "guideline_ids": [
                "GL-JAN-MS",
                "GL-ADA"
              ]
            }
          ],
          "follow_up": "Ocrelizumab infusions in two and four weeks at the infusion center. Review six weeks after the second infusion with a blood count, CD19 count, vitamin D and the PHQ-9",
          "guideline_ids": [
            "GL-AAN-DMT-2018",
            "GL-MAGNIMS-2021",
            "GL-AAN-VAX-2019",
            "GL-OCR-LABEL",
            "GL-NICE-MS-2022",
            "GL-CDC-IMZ-2026",
            "GL-CMID-2026",
            "GL-JAN-MS",
            "GL-ADA"
          ]
        }
      },
      {
        "id": "ENC-004",
        "display": "Four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood",
        "status": "finished",
        "date": "2026-06-29",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-04"
        },
        "documentation": {
          "chief_complaint": "Four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood",
          "hpi": {
            "narrative": "Ms. Jordan returns six weeks after her second ocrelizumab half-dose. During the first infusion she had a scratchy throat that settled when the infusion was slowed; the second infusion went without a reaction. She has had no infections, cold sores, or diarrhea. Physical therapy started four weeks ago through a second provider, after the first service could not offer a date; she has had six sessions and does her home program most days, and she now uses a rollator at home for longer distances. Summer has brought heat sensitivity: her legs feel heavier on hot afternoons and recover when she cools down, and she has started using a cooling vest. She gets up once a night or less. Her mood is steady.",
            "elements": [
              {
                "label": "Infusions",
                "value": "Mild throat irritation with the first, settled by slowing; none with the second"
              },
              {
                "label": "Infections",
                "value": "None"
              },
              {
                "label": "Physical therapy",
                "value": "Started four weeks ago through a second provider; six sessions"
              },
              {
                "label": "Heat",
                "value": "Legs heavier on hot afternoons, recover with cooling"
              },
              {
                "label": "Mood",
                "value": "PHQ-9 3"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Afternoon fatigue, worse in the heat; no fever"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "No diarrhea or abdominal pain"
            },
            {
              "system": "Genitourinary",
              "status": "negative",
              "finding": "Up once a night or less; no burning"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No rash or cold sores"
            },
            {
              "system": "Neurological",
              "status": "positive",
              "finding": "Temporary heaviness of the legs in the heat; no new symptom lasting more than a day"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood steady"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; blood pressure 118/74, pulse 74; temperature 36.8 °C"
            },
            {
              "system": "Neurological",
              "finding": "Spastic gait with a cane, as before; modified Ashworth 1+ in both legs; EDSS 6.0; timed 25-foot walk 11.1 seconds"
            },
            {
              "system": "Skin",
              "finding": "No rash"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Active primary progressive multiple sclerosis",
              "assessment": "Ocrelizumab started, with a mild first-infusion reaction only. White cells 5.9, lymphocytes 1.4, hemoglobin 13.4 g/dL, platelets 248; CD19 B cells 3 per microliter, depleted as expected; ALT 20 U/L. Disability stable. The heat-related heaviness is pseudo-relapse, not new disease activity",
              "plan": [
                "Next dose, 600 mg, six months after the first half-dose",
                "Re-baseline brain MRI before the October review",
                "Cooling vest, air conditioning and cool drinks; morning teaching where she can"
              ]
            },
            {
              "problem_id": "PRB-005",
              "display": "Vitamin D deficiency",
              "assessment": "25-hydroxyvitamin D 34 ng/mL after four months of vitamin D3: replete",
              "plan": [
                "Continue vitamin D3 2000 units daily; recheck yearly",
                "Bone density at the preventive visit"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Spastic gait and fall risk",
              "assessment": "Physical therapy under way; rollator for longer distances at home; no falls",
              "plan": [
                "Continue physical therapy and the home program",
                "Scooter assessment for campus distances when she wants one"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "examination",
              "measure": "New or worsening symptoms (relapse, pseudo-relapse with heat or infection)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No relapse; heat-related pseudo-relapse explained",
              "guideline_ids": [
                "GL-AAN-DMT-2018",
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "examination",
              "measure": "Disability: EDSS and timed 25-foot walk",
              "cadence": "Every visit, and at least every 6 months",
              "status": "completed_today",
              "detail": "EDSS 6.0; timed 25-foot walk 11.1 seconds",
              "guideline_ids": [
                "GL-AAN-DMT-2018"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Infusion reactions and infections",
              "cadence": "Each infusion, and every visit",
              "status": "completed_today",
              "detail": "Mild throat irritation with the first infusion, settled by slowing; none with the second; no infections since",
              "guideline_ids": [
                "GL-OCR-LABEL"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Blood count with absolute lymphocytes",
              "cadence": "Before the first dose, then before each dose",
              "status": "completed_today",
              "detail": "White cells 5.9, lymphocytes 1.4, hemoglobin 13.4, platelets 248; CD19 3 per microliter (depleted, expected)",
              "observation_ids": [
                "OBS-WBC-V4",
                "OBS-LYMPH-V4",
                "OBS-HGB-V4",
                "OBS-PLT-V4",
                "OBS-CD19-V4"
              ],
              "guideline_ids": [
                "GL-OCR-LABEL",
                "GL-AAN-DMT-2018"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Liver tests",
              "cadence": "Before the first dose, then with symptoms and before each dose",
              "status": "completed_today",
              "detail": "ALT 20 U/L",
              "observation_ids": [
                "OBS-ALT-V4"
              ],
              "guideline_ids": [
                "GL-OCR-LABEL"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Hepatitis B surface antibody after vaccination",
              "cadence": "One to two months after the series in someone on immune therapy",
              "status": "completed_today",
              "detail": "Protective level after two doses",
              "guideline_ids": [
                "GL-AAN-VAX-2019",
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Spasticity (modified Ashworth) and baclofen tolerance",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Modified Ashworth 1+ on baclofen 10 mg three times a day",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "examination",
              "measure": "Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Nocturia once or less; blood pressure 118/74 on mirabegron",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "referral",
              "measure": "Falls, walking aids and physical therapy",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Physical therapy started four weeks ago through a second provider; rollator at home; no falls",
              "guideline_ids": [
                "GL-NICE-MS-2022",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Fatigue and heat sensitivity",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Heat sensitivity; cooling vest started",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "25-hydroxyvitamin D",
              "cadence": "At baseline, 8 to 12 weeks after repletion, then yearly",
              "status": "completed_today",
              "detail": "34 ng/mL after repletion",
              "observation_ids": [
                "OBS-VITD-V4"
              ],
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Bone density",
              "cadence": "Once for reduced mobility and earlier steroid courses; repeat by risk",
              "status": "due",
              "detail": "At the preventive visit",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "survey",
              "measure": "Depression screen (PHQ-9)",
              "cadence": "At intake, then every 6 months and with any change",
              "status": "completed_today",
              "detail": "PHQ-9 3",
              "observation_ids": [
                "OBS-PHQ9-V4"
              ],
              "guideline_ids": [
                "GL-USPSTF-DEP-2023",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "examination",
              "measure": "Concentration and word-finding",
              "cadence": "At intake, then yearly or with concern",
              "status": "completed_today",
              "detail": "No concern raised by her; lectures and writing unaffected",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Breast cancer screening (ocrelizumab label: standard screening)",
              "cadence": "Every two years from 40",
              "status": "due",
              "detail": "Mammogram to be ordered at the preventive visit",
              "guideline_ids": [
                "GL-OCR-LABEL"
              ]
            }
          ],
          "follow_up": "Preventive visit in seven weeks with bone density and the mammogram order. Re-baseline brain MRI and review in four months, before the 600 mg dose",
          "guideline_ids": [
            "GL-AAN-DMT-2018",
            "GL-OCR-LABEL",
            "GL-AAN-VAX-2019",
            "GL-NICE-MS-2022",
            "GL-CMID-2026",
            "GL-USPSTF-DEP-2023",
            "GL-CDC-IMZ-2026"
          ]
        }
      },
      {
        "id": "ENC-005",
        "display": "Eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work",
        "status": "finished",
        "date": "2026-10-26",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic modern EHR encounter.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        },
        "visit_type": "chronic_care",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "390906007",
          "display": "Follow-up encounter",
          "validation_status": "validated",
          "validated_on": "2026-11-04"
        },
        "documentation": {
          "chief_complaint": "Eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work",
          "hpi": {
            "narrative": "Ms. Jordan returns ten weeks after her preventive visit, with a re-baseline brain MRI this morning. She has had no new symptoms and no infection since her first doses. Her mammogram in August was normal, and her HPV test was negative. The heat sensitivity eased as the weather cooled. She finished her course of physical therapy and keeps up her home program and pool exercise; she has had no falls since the near-fall in July. She is teaching a full term and gave two public lectures this month, seated at a lectern. She gets up once a night or less. Dr. Watanabe has reviewed the MRI. Her next infusion, the first full 600 mg dose, is booked in two weeks.",
            "elements": [
              {
                "label": "New symptoms",
                "value": "None"
              },
              {
                "label": "Screening",
                "value": "Mammogram normal; HPV negative"
              },
              {
                "label": "Falls",
                "value": "None; one near-fall in July"
              },
              {
                "label": "Work",
                "value": "Full teaching term and public lectures"
              },
              {
                "label": "Next infusion",
                "value": "600 mg in two weeks"
              }
            ]
          },
          "ros": [
            {
              "system": "Constitutional",
              "status": "negative",
              "finding": "No fever, infection or weight change"
            },
            {
              "system": "Respiratory",
              "status": "negative",
              "finding": "No cough"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "No diarrhea"
            },
            {
              "system": "Genitourinary",
              "status": "negative",
              "finding": "No burning; nocturia once or less"
            },
            {
              "system": "Neurological",
              "status": "negative",
              "finding": "No new numbness, weakness or visual change"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood steady"
            }
          ],
          "exam": [
            {
              "system": "General",
              "finding": "Well; weight 83.2 kg; blood pressure 120/76, pulse 72; temperature 36.6 °C"
            },
            {
              "system": "Neurological",
              "finding": "Spastic gait with a cane; modified Ashworth 1+ in both legs; hip flexor strength 4 out of 5; EDSS 6.0; timed 25-foot walk 11.0 seconds"
            },
            {
              "system": "Skin",
              "finding": "No rash or cold sores"
            }
          ],
          "assessment_plan": [
            {
              "problem_id": "PRB-002",
              "display": "Active primary progressive multiple sclerosis",
              "assessment": "Re-baseline brain MRI without gadolinium: no new or enlarging T2 lesions compared with the diagnostic scan. Disability stable at EDSS 6.0 with a steady timed walk. White cells 6.1, lymphocytes 1.5, hemoglobin 13.5 g/dL, platelets 255; IgG 1010 and IgM 72 mg/dL, both normal; ALT 19 and AST 21 U/L; creatinine 0.80 mg/dL. Safe to give the 600 mg dose",
              "plan": [
                "Ocrelizumab 600 mg in two weeks, with premedication",
                "Influenza and COVID-19 vaccines today, two weeks before the infusion",
                "Next brain MRI in one year; immunoglobulins and blood count before each dose",
                "Dr. Watanabe to review in six months"
              ]
            },
            {
              "problem_id": "PRB-003",
              "display": "Spastic gait and fall risk",
              "assessment": "No falls since one near-fall in the July heat; physical therapy completed",
              "plan": [
                "Continue the home program, pool exercise and baclofen 10 mg three times a day",
                "Scooter assessment remains open to her"
              ]
            },
            {
              "problem_id": "PRB-004",
              "display": "Neurogenic bladder",
              "assessment": "Controlled on mirabegron; blood pressure normal",
              "plan": [
                "Continue mirabegron 25 mg daily"
              ]
            }
          ],
          "monitoring": [
            {
              "domain": "examination",
              "measure": "New or worsening symptoms (relapse, pseudo-relapse with heat or infection)",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "No relapse in eight months",
              "guideline_ids": [
                "GL-AAN-DMT-2018",
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "examination",
              "measure": "Disability: EDSS and timed 25-foot walk",
              "cadence": "Every visit, and at least every 6 months",
              "status": "completed_today",
              "detail": "EDSS 6.0; timed 25-foot walk 11.0 seconds",
              "guideline_ids": [
                "GL-AAN-DMT-2018"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Brain MRI",
              "cadence": "At diagnosis with gadolinium; re-baseline 3 to 6 months after starting therapy; then yearly without routine gadolinium",
              "status": "completed_today",
              "detail": "Re-baseline without gadolinium, five to six months after the first dose: no new or enlarging T2 lesions; next in one year",
              "guideline_ids": [
                "GL-MAGNIMS-2021"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Spinal cord MRI",
              "cadence": "At diagnosis; later only for new spinal symptoms or diagnostic doubt",
              "status": "not_indicated",
              "detail": "No new spinal symptoms",
              "guideline_ids": [
                "GL-MAGNIMS-2021"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Blood count with absolute lymphocytes",
              "cadence": "Before the first dose, then before each dose",
              "status": "completed_today",
              "detail": "White cells 6.1, lymphocytes 1.5, hemoglobin 13.5, platelets 255",
              "observation_ids": [
                "OBS-WBC-V5",
                "OBS-LYMPH-V5",
                "OBS-HGB-V5",
                "OBS-PLT-V5"
              ],
              "guideline_ids": [
                "GL-OCR-LABEL",
                "GL-AAN-DMT-2018"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Quantitative immunoglobulins",
              "cadence": "Before the first dose, then before each dose",
              "status": "completed_today",
              "detail": "IgG 1010, IgM 72 mg/dL",
              "observation_ids": [
                "OBS-IGG-V5",
                "OBS-IGM-V5"
              ],
              "guideline_ids": [
                "GL-OCR-LABEL"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "Liver tests",
              "cadence": "Before the first dose, then with symptoms and before each dose",
              "status": "completed_today",
              "detail": "ALT 19, AST 21 U/L; creatinine 0.80 mg/dL",
              "observation_ids": [
                "OBS-ALT-V5",
                "OBS-AST-V5",
                "OBS-CR-V5",
                "OBS-EGFR-V5"
              ],
              "guideline_ids": [
                "GL-OCR-LABEL"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Infusion reactions and infections",
              "cadence": "Each infusion, and every visit",
              "status": "completed_today",
              "detail": "No infections; 600 mg dose booked in two weeks",
              "guideline_ids": [
                "GL-OCR-LABEL"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Influenza and COVID-19 vaccines",
              "cadence": "Each season, ideally at least 2 weeks before an infusion",
              "status": "completed_today",
              "detail": "Both given today",
              "guideline_ids": [
                "GL-AAN-VAX-2019",
                "GL-CDC-IMZ-2026"
              ]
            },
            {
              "domain": "medication_safety",
              "measure": "Breast cancer screening (ocrelizumab label: standard screening)",
              "cadence": "Every two years from 40",
              "status": "up_to_date",
              "detail": "Mammogram normal in August",
              "guideline_ids": [
                "GL-OCR-LABEL",
                "GL-USPSTF-BRCA-2024"
              ]
            },
            {
              "domain": "examination",
              "measure": "Spasticity (modified Ashworth) and baclofen tolerance",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Modified Ashworth 1+",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "examination",
              "measure": "Bladder: urgency, nocturia, urinary infection, and blood pressure on mirabegron",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Nocturia once or less; blood pressure 120/76",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "referral",
              "measure": "Falls, walking aids and physical therapy",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Physical therapy course completed; no falls",
              "guideline_ids": [
                "GL-NICE-MS-2022",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Fatigue and heat sensitivity",
              "cadence": "Every visit",
              "status": "completed_today",
              "detail": "Heat sensitivity eased with cooler weather",
              "guideline_ids": [
                "GL-NICE-MS-2022"
              ]
            },
            {
              "domain": "laboratory",
              "measure": "25-hydroxyvitamin D",
              "cadence": "At baseline, 8 to 12 weeks after repletion, then yearly",
              "status": "up_to_date",
              "detail": "34 ng/mL four months ago; recheck at one year",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "imaging",
              "measure": "Bone density",
              "cadence": "Once for reduced mobility and earlier steroid courses; repeat by risk",
              "status": "up_to_date",
              "detail": "Normal for age at the preventive visit",
              "guideline_ids": [
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "survey",
              "measure": "Depression screen (PHQ-9)",
              "cadence": "At intake, then every 6 months and with any change",
              "status": "due",
              "detail": "PHQ-9 3 four months ago and PHQ-2 0 ten weeks ago; next PHQ-9 at the next review",
              "guideline_ids": [
                "GL-USPSTF-DEP-2023",
                "GL-CMID-2026"
              ]
            },
            {
              "domain": "self_management",
              "measure": "Workplace accommodation",
              "cadence": "At intake and with any change",
              "status": "completed_today",
              "detail": "Accommodations working; no change needed",
              "guideline_ids": [
                "GL-JAN-MS",
                "GL-ADA"
              ]
            },
            {
              "domain": "referral",
              "measure": "Multiple sclerosis neurology review",
              "cadence": "At diagnosis, then every 6 months on therapy",
              "status": "completed_today",
              "detail": "Dr. Watanabe reviewed the MRI and results and agreed with the plan; review in six months",
              "guideline_ids": [
                "GL-AAN-DMT-2018"
              ]
            }
          ],
          "follow_up": "Ocrelizumab 600 mg in two weeks. Review in three months with the PHQ-9, or the same day for new or worsening symptoms lasting more than 24 hours, fever, or a persistent infection",
          "guideline_ids": [
            "GL-AAN-DMT-2018",
            "GL-MAGNIMS-2021",
            "GL-OCR-LABEL",
            "GL-AAN-VAX-2019",
            "GL-CDC-IMZ-2026",
            "GL-NICE-MS-2022",
            "GL-CMID-2026",
            "GL-USPSTF-DEP-2023",
            "GL-JAN-MS",
            "GL-ADA",
            "GL-USPSTF-BRCA-2024"
          ]
        }
      },
      {
        "id": "ENC-006",
        "display": "Periodic adult preventive visit",
        "status": "finished",
        "date": "2026-08-17",
        "visit_type": "preventive_adult",
        "type_coding": {
          "system": "http://snomed.info/sct",
          "code": "86013001",
          "display": "Periodic reevaluation and management of healthy individual",
          "validation_status": "validated",
          "validated_on": "2026-11-04"
        },
        "documentation": {
          "chief_complaint": "Periodic adult preventive visit",
          "billing_note": "CPT 99396 (periodic preventive medicine, established patient, age 40 to 64) with CPT 99497 (advance care planning), both on the same day",
          "health_risk_assessment_method": "Completed by the patient on the clinic's online form before the visit and reviewed with her by Dr. Moss",
          "hpi": {
            "narrative": "Ms. Jordan is a 44-year-old professor with active primary progressive multiple sclerosis who comes for her yearly preventive visit seven weeks after her four-month review. She had her two ocrelizumab half-doses three months ago and has had no infections since. Her walking is unchanged: she uses her cane on campus and a rollator at home for longer distances. The summer heat makes her legs heavier by the afternoon; her cooling vest and moving her seminars to the morning have helped. She has had no falls; on one hot afternoon in July her legs gave way briefly at home and her rollator caught her. Her bladder is better on mirabegron. She is preparing for the autumn term and several speaking engagements, and her university has put the accommodations she asked for in place. She had her bone density scan this morning.",
            "elements": [
              {
                "label": "Visit",
                "value": "Periodic adult preventive visit, age 44"
              },
              {
                "label": "Multiple sclerosis",
                "value": "Ocrelizumab started three months ago; walking unchanged; no relapse"
              },
              {
                "label": "Heat",
                "value": "Legs heavier in the afternoon heat; cooling vest helps"
              },
              {
                "label": "Mood",
                "value": "PHQ-2 0"
              }
            ]
          },
          "health_risk_assessment": [
            {
              "domain": "Self-rated health",
              "finding": "Good"
            },
            {
              "domain": "Psychosocial",
              "finding": "Engaged in her teaching and public work; good supports of her choosing; low stress apart from the term's start"
            },
            {
              "domain": "Substance use",
              "finding": "No tobacco; occasional alcohol within low-risk limits; no drug use"
            },
            {
              "domain": "Physical activity",
              "finding": "Home exercise program from physical therapy most days; pool exercise twice a week in cool water"
            },
            {
              "domain": "Nutrition",
              "finding": "Regular meals; dairy at most meals for calcium; takes vitamin D3"
            },
            {
              "domain": "Sleep",
              "finding": "Seven hours; up once a night at most"
            },
            {
              "domain": "Falls and home safety",
              "finding": "No falls this year; one near-fall in the July heat; grab bars and a shower seat installed; no loose rugs"
            },
            {
              "domain": "Driving",
              "finding": "Drives safely by her account; no hand-control need at present"
            },
            {
              "domain": "Work",
              "finding": "Accessible room, chair and lectern, and reserved parking in place"
            },
            {
              "domain": "Activities of daily living",
              "finding": "Independent; tires by late afternoon"
            },
            {
              "domain": "Seat belt and smoke alarms",
              "finding": "Always wears a seat belt; smoke alarms tested"
            }
          ],
          "ros": [
            {
              "system": "Constitutional",
              "status": "positive",
              "finding": "Fatigue by late afternoon, worse in the heat; no fever or weight change"
            },
            {
              "system": "Eyes",
              "status": "negative",
              "finding": "No blurred or double vision"
            },
            {
              "system": "Ears, nose, mouth, and throat",
              "status": "negative",
              "finding": "No hearing change or sore mouth"
            },
            {
              "system": "Cardiovascular",
              "status": "negative",
              "finding": "No chest pain or leg swelling"
            },
            {
              "system": "Respiratory",
              "status": "negative",
              "finding": "No cough or breathlessness"
            },
            {
              "system": "Gastrointestinal",
              "status": "negative",
              "finding": "Regular bowels; no diarrhea"
            },
            {
              "system": "Genitourinary",
              "status": "negative",
              "finding": "Urgency improved; up once a night at most; no burning"
            },
            {
              "system": "Breast",
              "status": "negative",
              "finding": "No lump or nipple change"
            },
            {
              "system": "Musculoskeletal",
              "status": "positive",
              "finding": "Leg stiffness in the mornings, eased by stretching"
            },
            {
              "system": "Integumentary",
              "status": "negative",
              "finding": "No rash or cold sores"
            },
            {
              "system": "Neurological",
              "status": "positive",
              "finding": "Legs heavier in the heat, settling when she cools down; no new numbness or weakness lasting more than a day"
            },
            {
              "system": "Psychiatric",
              "status": "negative",
              "finding": "Mood steady; PHQ-2 0"
            }
          ],
          "exam": [
            {
              "system": "Constitutional",
              "finding": "Well; weight 83.4 kg; blood pressure 118/74"
            },
            {
              "system": "Eyes",
              "finding": "Pupils equal and reactive; no nystagmus"
            },
            {
              "system": "Neck",
              "finding": "No thyroid enlargement or lymph nodes"
            },
            {
              "system": "Breasts",
              "finding": "Clinical breast examination with a chaperone, at her choice: no masses, skin or nipple changes, or axillary nodes"
            },
            {
              "system": "Cardiovascular",
              "finding": "Regular rhythm; no murmur; no leg swelling"
            },
            {
              "system": "Respiratory",
              "finding": "Clear"
            },
            {
              "system": "Abdomen",
              "finding": "Soft, non-tender"
            },
            {
              "system": "Skin",
              "finding": "No rash or suspicious lesions"
            },
            {
              "system": "Neurological",
              "finding": "Spastic gait with the cane, as before; modified Ashworth 1+ in both legs; strength 4 out of 5 in the hip flexors; brisk leg reflexes"
            },
            {
              "system": "Psychiatric",
              "finding": "Engaged and precise"
            }
          ],
          "assessment_plan": [
            {
              "display": "Periodic adult preventive visit completed",
              "assessment": "Health risk assessment reviewed and the prevention plan updated. Mammogram ordered: screening every two years from 40 is recommended, and the ocrelizumab label advises standard breast cancer screening. Cervical screening with HPV testing done today. Bone density today: lumbar spine and hip Z-scores -0.4 and -0.6, within the expected range for age. A1c 5.4%; LDL 110 mg/dL with a low ten-year risk",
              "plan": [
                "Mammogram this month",
                "Influenza and COVID-19 vaccines at the October review, at least two weeks before her next infusion",
                "Colorectal cancer screening from 45",
                "Next preventive visit in one year"
              ]
            },
            {
              "problem_id": "PRB-002",
              "display": "Active primary progressive multiple sclerosis",
              "assessment": "Stable on ocrelizumab; heat brings temporary heaviness in her legs that settles with cooling, which is pseudo-relapse, not new disease activity. She chose to complete advance care planning today",
              "plan": [
                "Continue cooling measures and morning teaching",
                "Re-baseline brain MRI before the October review"
              ]
            },
            {
              "problem_id": "PRB-005",
              "display": "Vitamin D deficiency",
              "assessment": "Replete on vitamin D3; bone density normal for age",
              "plan": [
                "Continue vitamin D3 2000 units daily and calcium from food",
                "Repeat bone density only if steroid courses accumulate, a fracture occurs, or at menopause"
              ]
            }
          ],
          "prevention_plan": [
            {
              "service": "Blood pressure screening",
              "status": "completed_today",
              "detail": "118/74 mmHg",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Depression screening",
              "status": "completed_today",
              "detail": "PHQ-2 score 0; PHQ-9 3 seven weeks ago",
              "guideline_ids": [
                "GL-USPSTF-DEP-2023"
              ]
            },
            {
              "service": "Unhealthy alcohol use screening",
              "status": "completed_today",
              "detail": "Occasional use within low-risk limits",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Tobacco use",
              "status": "completed_today",
              "detail": "Never",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Breast cancer screening",
              "status": "ordered",
              "detail": "Mammogram every two years from 40; no previous mammogram on file; ordered today, with the ocrelizumab label's advice to follow standard screening",
              "guideline_ids": [
                "GL-USPSTF-BRCA-2024",
                "GL-OCR-LABEL"
              ]
            },
            {
              "service": "Cervical cancer screening",
              "status": "completed_today",
              "detail": "Primary HPV test with a chaperone present, after she was told each step and agreed; result by phone",
              "guideline_ids": [
                "GL-USPSTF-CERV-2018"
              ]
            },
            {
              "service": "Colorectal cancer screening",
              "status": "not_indicated",
              "detail": "Begins at 45, next year; she prefers a stool test",
              "guideline_ids": [
                "GL-USPSTF-CRC-2021"
              ]
            },
            {
              "service": "Diabetes and lipid screening",
              "status": "completed_today",
              "detail": "A1c 5.4%; total cholesterol 186, LDL 110, HDL 56, triglycerides 98 mg/dL; ten-year risk low, no statin",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "HIV and hepatitis C screening",
              "status": "up_to_date",
              "detail": "Both negative at intake",
              "guideline_ids": [
                "GL-USPSTF-AB"
              ]
            },
            {
              "service": "Bone density",
              "status": "completed_today",
              "detail": "Z-scores -0.4 at the spine and -0.6 at the hip; done for reduced mobility and earlier steroid courses",
              "guideline_ids": [
                "GL-CMID-2026",
                "GL-NICE-MS-2022"
              ]
            },
            {
              "service": "Pneumococcal, zoster, Tdap and hepatitis B vaccines",
              "status": "up_to_date",
              "detail": "PCV20, both recombinant zoster doses, Tdap and both hepatitis B doses given before ocrelizumab",
              "guideline_ids": [
                "GL-CDC-IMZ-2026",
                "GL-AAN-VAX-2019"
              ]
            },
            {
              "service": "Influenza and COVID-19 vaccines, this season",
              "status": "due",
              "detail": "At the October review, at least two weeks before the next infusion",
              "guideline_ids": [
                "GL-CDC-IMZ-2026",
                "GL-AAN-VAX-2019"
              ]
            },
            {
              "service": "Live vaccines",
              "status": "not_indicated",
              "detail": "Not recommended on ocrelizumab; varicella and measles immunity documented before treatment",
              "guideline_ids": [
                "GL-OCR-LABEL",
                "GL-AAN-VAX-2019"
              ]
            },
            {
              "service": "Dental and eye examinations",
              "status": "due",
              "detail": "Dental review and an eye examination advised this year",
              "guideline_ids": [
                "GL-PREV-2026"
              ]
            }
          ],
          "advance_care_planning": "Voluntary advance care planning discussion of about 20 minutes, with her consent. She wants full treatment for any illness that could be reversed, wants to be told plainly what is happening, and wants to make her own decisions. She named a health care agent, recorded in the confidential part of the chart and not named here, and asked that information about her health be shared only with the people she names. She chose not to record other treatment preferences today. To be revisited yearly or after any serious illness.",
          "follow_up": "Mammogram this month; HPV result by phone. Re-baseline brain MRI and the eight-month review in October, with influenza and COVID-19 vaccines. Next preventive visit in one year",
          "guideline_ids": [
            "GL-PREV-2026",
            "GL-USPSTF-AB",
            "GL-USPSTF-BRCA-2024",
            "GL-USPSTF-CERV-2018",
            "GL-CDC-IMZ-2026",
            "GL-OCR-LABEL"
          ]
        },
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic periodic preventive visit.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "vital_sign_sets": [
      {
        "id": "VSET-001",
        "date": "2026-03-02",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 173,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 84.0,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 28.1,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 124,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 78,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 76,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.7,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic vital signs, seated. No measurement from her life is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "VSET-002",
        "date": "2026-03-16",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 173,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 84.2,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 28.1,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 122,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 76,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 74,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs, seated. No measurement from her life is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "VSET-003",
        "date": "2026-04-20",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 173,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 83.8,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 28.0,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 120,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 76,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 72,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 99,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs, seated. No measurement from her life is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "VSET-004",
        "date": "2026-06-29",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 173,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 83.5,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 27.9,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 118,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 74,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 74,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.8,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs, seated. No measurement from her life is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "VSET-005",
        "date": "2026-10-26",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 173,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 83.2,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 27.8,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 120,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 76,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 72,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.6,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs, seated. No measurement from her life is used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "VSET-006",
        "date": "2026-08-17",
        "measurements": [
          {
            "code": "8302-2",
            "display": "Body height",
            "value": 173,
            "unit": "cm"
          },
          {
            "code": "29463-7",
            "display": "Body weight",
            "value": 83.4,
            "unit": "kg"
          },
          {
            "code": "39156-5",
            "display": "Body mass index (BMI) [Ratio]",
            "value": 27.9,
            "unit": "kg/m2"
          },
          {
            "code": "8480-6",
            "display": "Systolic blood pressure",
            "value": 118,
            "unit": "mm[Hg]"
          },
          {
            "code": "8462-4",
            "display": "Diastolic blood pressure",
            "value": 74,
            "unit": "mm[Hg]"
          },
          {
            "code": "8867-4",
            "display": "Heart rate",
            "value": 74,
            "unit": "/min"
          },
          {
            "code": "9279-1",
            "display": "Respiratory rate",
            "value": 16,
            "unit": "/min"
          },
          {
            "code": "8310-5",
            "display": "Body temperature",
            "value": 36.7,
            "unit": "Cel"
          },
          {
            "code": "59408-5",
            "display": "Oxygen saturation in Arterial blood by Pulse oximetry",
            "value": 98,
            "unit": "%"
          }
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic vital signs at the preventive visit, seated.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "social_history": [
      {
        "id": "SOC-001",
        "display": "Professor at a school of public affairs, teaching seminars on policy and ethics; a frequent public speaker; formerly a state senator and member of Congress",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0002",
            "CLM-0003",
            "CLM-0004"
          ],
          "synthetic_reason": "Synthetic modern work history anchored to her documented career.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "SOC-002",
        "display": "Lives in a single-story home in Austin; household details not recorded, at her request; drives to work",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic home details; no person is named or given a role.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "SOC-003",
        "display": "Keeps her diagnosis private; has told only those she chooses, and wants any letter to her employer to describe her needs, not her diagnosis",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic preference anchored to the public accounts that she kept the disease private.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "SOC-004",
        "display": "Tobacco: never. Alcohol: occasional, within low-risk limits. No drug use reported",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic entry for the modern episode; her real use was not researched and is not used.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "SOC-005",
        "display": "Exercise: walks short distances; swimming was suggested to her before but she has not started",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic exercise history.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "functional_status": [
      {
        "id": "FUNC-001",
        "display": "Walks about 100 meters with a cane in her right hand before needing to rest (EDSS 6.0); timed 25-foot walk 11.2 seconds; climbs stairs with a rail; independent in self-care; drives; tires by mid-afternoon",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic functional status anchored to her documented cane.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "mental_status": [
      {
        "id": "MSE-001",
        "display": "Alert, precise and articulate; mood steady; frustrated by fatigue; PHQ-9 score 6, mostly from fatigue and sleep items; no thoughts of self-harm",
        "status": "current",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mental-status finding; not a claim about her real mood.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "consultation": {
      "referral": {
        "question": "Multiple sclerosis diagnosed elsewhere in a 44-year-old professor and public speaker who walks with a cane, with records of the original evaluation not available. Please confirm and classify the disease on the MRI booked for the morning of your visit, and advise on disease-modifying therapy, its screening and monitoring, vaccination, symptom care and MRI follow-up",
        "urgency": "Within two weeks, on the same day as her two-week primary care visit",
        "pertinent_history": "By her account multiple sclerosis was diagnosed elsewhere some years ago; she has no records and recalls no attack that came on over days and recovered. Her walking has worsened slowly over the past few years: she began using a cane while still in her previous public office, and now rests after about 100 meters. Leg stiffness, afternoon fatigue, heat sensitivity, urinary urgency and nocturia twice. Two near-falls and no falls in the past year. No previous disease-modifying therapy; she recalls steroid courses in the past. Today: blood pressure 124/78, weight 84.0 kg, BMI 28.1; spastic paraparetic gait with a cane; post-void residual 40 mL by bladder scan; PHQ-9 6. Results today: white cells 6.4, lymphocytes 1.9, hemoglobin 13.2 g/dL, platelets 262; creatinine 0.78 mg/dL, eGFR 96; ALT 18, AST 20, alkaline phosphatase 72 U/L, bilirubin 0.5 mg/dL; TSH 1.8; vitamin B12 520 pg/mL; 25-hydroxyvitamin D 17 ng/mL, so vitamin D3 started; IgG 1080, IgM 110, IgA 210 mg/dL; JC virus antibody index 0.14. Hepatitis B serology, varicella and measles immunity, tuberculosis blood test, HIV and hepatitis C are pending. MRI of the brain and cervical and thoracic spine with gadolinium is booked for the morning of your visit. She keeps her diagnosis private and decides who receives this letter",
        "questions": [
          "Does she meet the 2017 McDonald criteria, and is her course relapsing or progressive, active or not active?",
          "Which disease-modifying therapy, if any, do you advise, and why?",
          "What screening and vaccination are needed before the first dose, and how long before?",
          "What monitoring will the therapy need?",
          "When should the MRI be repeated, and with what protocol?",
          "What do you advise for spasticity, bladder urgency, fatigue and heat sensitivity?",
          "How should she recognize and report a relapse?"
        ]
      },
      "consultant_note": {
        "history": "Ms. Jordan, a 44-year-old professor and public speaker, is seen at the request of Dr. Moss. She was told years ago that she had multiple sclerosis; the records are not available. She describes slowly worsening walking over several years, needing a cane for some time, with no attack of new symptoms over days that then recovered. She has leg stiffness, afternoon fatigue, heat sensitivity, urinary urgency and nocturia, and no visual loss or double vision. She has had steroid courses in the past and no disease-modifying therapy. She wants to know whether a treatment can slow the disease, and wants to keep teaching and speaking",
        "data_reviewed": "Dr. Moss's intake note and results: blood count, kidney and liver tests, TSH, vitamin B12 and immunoglobulins normal; 25-hydroxyvitamin D 17 ng/mL; JC virus antibody index 0.14, negative. Results since intake: hepatitis B surface antigen, core antibody and surface antibody negative; varicella IgG and measles, mumps and rubella IgG positive; tuberculosis blood test, HIV and hepatitis C negative. MRI this morning, brain with gadolinium: fourteen T2 lesions, periventricular, juxtacortical, and infratentorial in the pons and left middle cerebellar peduncle, with one enhancing right periventricular lesion. Cervical and thoracic spine: three cord lesions at C3, C5 and T6, each shorter than two segments, with no compression",
        "exam": [
          {
            "system": "General",
            "finding": "Well; blood pressure 122/76"
          },
          {
            "system": "Cranial nerves",
            "finding": "Visual acuity 20/20 in each eye; no relative afferent pupillary defect; full eye movements without nystagmus"
          },
          {
            "system": "Motor",
            "finding": "Hip flexor strength 4 out of 5 on both sides; modified Ashworth 2 in both legs"
          },
          {
            "system": "Reflexes",
            "finding": "Brisk in the legs with extensor plantar responses"
          },
          {
            "system": "Sensory",
            "finding": "Reduced vibration sense at the toes"
          },
          {
            "system": "Gait",
            "finding": "Spastic paraparetic gait with a cane; EDSS 6.0; timed 25-foot walk 11.0 seconds"
          }
        ],
        "assessment": [
          {
            "problem_id": "PRB-002",
            "display": "Active primary progressive multiple sclerosis",
            "assessment": "More than a year of gradually worsening disability without relapses, with T2 lesions in characteristic brain regions and two or more spinal cord lesions, meets the 2017 McDonald criteria for primary progressive multiple sclerosis without the need for spinal fluid. The enhancing lesion shows inflammatory activity, so the disease is active. B12, thyroid and HIV results and the absence of cord compression exclude the main mimics. At 44, still walking with a cane, with an enhancing lesion, she is the kind of patient most likely to benefit from therapy"
          },
          {
            "problem_id": "PRB-003",
            "display": "Spastic gait and fall risk",
            "assessment": "Spasticity contributes to her slowness and stiffness; strength is fairly preserved, so a careful baclofen titration should not weaken her"
          },
          {
            "problem_id": "PRB-004",
            "display": "Neurogenic bladder",
            "assessment": "Urgency with a low residual; safe to treat with a bladder-relaxing medicine, preferably one without anticholinergic effects on concentration"
          }
        ],
        "recommendations": [
          "Ocrelizumab, the therapy with evidence for primary progressive multiple sclerosis: 300 mg intravenously on day 1 and day 15, then 600 mg every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen beforehand and at least one hour of observation; twice-yearly infusions suit her teaching and travel",
          "Before the first dose: she is not infected with hepatitis B but not immune, so hepatitis B vaccine; PCV20, recombinant zoster vaccine (two doses, the second after about a month), and Tdap; inactivated vaccines at least two weeks before the first dose and live vaccines at least four weeks before (none needed, as she is immune to varicella and measles); confirm no active infection on each infusion day",
          "Monitoring: blood count with lymphocytes, liver tests and immunoglobulins before each dose; hepatitis B surface antibody after the series; prompt review of infections, persistent diarrhea or new neurological symptoms; standard breast cancer screening; no live vaccines during treatment; seasonal influenza and COVID-19 vaccines, ideally at least two weeks before an infusion",
          "MRI: a re-baseline brain MRI three to six months after the first dose, then yearly, on the same scanner where possible and without routine gadolinium; spinal MRI only for new spinal symptoms",
          "Spasticity: baclofen 5 mg three times a day, increasing to 10 mg three times a day once tolerated, with daily stretching and physical therapy; gabapentin is the second choice if baclofen fails",
          "Bladder: mirabegron 25 mg daily with timed voiding and a blood pressure check at each visit",
          "Fatigue and heat: pacing, morning teaching where she chooses, cooling garments and air conditioning, and aerobic exercise in cool water; no fatigue medicine for now",
          "Relapse plan: new or worsening symptoms lasting more than 24 hours without fever or heat mean a same-day call; check for urinary infection first; heat or infection can bring back old symptoms for hours without new disease activity",
          "Multiple sclerosis neurology review after the re-baseline MRI and then every six months"
        ],
        "communication": "Discussed with Dr. Moss, who sees her the same day. The plan was explained to Ms. Jordan, who agreed and decides who else receives this note; her reproductive plans were discussed privately and recorded in the confidential part of the chart",
        "follow_up": "Review after the re-baseline MRI, about seven months from now, then every six months; Dr. Moss continues primary care, vaccination and monitoring between visits"
      },
      "guideline_ids": [
        "GL-MCDONALD-2017",
        "GL-MAGNIMS-2021",
        "GL-AAN-DMT-2018",
        "GL-AAN-VAX-2019",
        "GL-OCR-LABEL",
        "GL-NICE-MS-2022",
        "GL-CDC-IMZ-2026"
      ]
    }
  },
  "care_plan": {
    "health_concerns": [
      {
        "id": "HC-001",
        "display": "She wants to keep teaching and speaking without her health becoming the subject",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0004"
          ],
          "synthetic_reason": "Synthetic patient-centered concern anchored to her documented privacy about the disease.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "HC-002",
        "display": "She wants to know whether any treatment can slow the disease",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic patient-centered concern.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "HC-003",
        "display": "She wants to stay safe on her feet and to have energy left at the end of a teaching day",
        "status": "active",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic patient-centered concern.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "goals": [
      {
        "id": "GOAL-001",
        "display": "Diagnosis confirmed and classified, vaccines completed at least two weeks before therapy, and a disease-modifying therapy started within ten weeks",
        "status": "completed",
        "target_date": "2026-06-29",
        "outcome": "Primary progressive disease confirmed at two weeks; vaccines finished at five weeks; ocrelizumab started at nine weeks",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "GOAL-002",
        "display": "No falls through eight months",
        "status": "completed",
        "target_date": "2026-10-26",
        "outcome": "No falls; one near-fall in the summer heat",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic safety goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "GOAL-003",
        "display": "25-hydroxyvitamin D at least 30 ng/mL within four months",
        "status": "completed",
        "target_date": "2026-06-29",
        "outcome": "34 ng/mL at four months",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bone health goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "GOAL-004",
        "display": "Up no more than once a night to pass urine within three months",
        "status": "completed",
        "target_date": "2026-06-29",
        "outcome": "Once a night or less on mirabegron",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bladder goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "GOAL-005",
        "display": "Keep her full teaching and speaking schedule with the accommodations she chooses",
        "status": "completed",
        "target_date": "2026-10-26",
        "outcome": "Full schedule kept; accessible rooms, seating and parking in place",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic work goal.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "GOAL-006",
        "display": "No new or enlarging T2 lesions on the re-baseline MRI",
        "status": "completed",
        "target_date": "2026-10-26",
        "outcome": "No new or enlarging T2 lesions",
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic disease activity goal; not a claim about her real course.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      }
    ],
    "interventions": [
      {
        "id": "INT-001",
        "display": "Confirm and classify the diagnosis: MRI of the brain and the cervical and thoracic spine with gadolinium to the MAGNIMS-CMSC-NAIMS protocol, read against the 2017 McDonald criteria; exclude mimics with vitamin B12, TSH and HIV; request the records of the original evaluation",
        "status": "completed",
        "guideline_ids": [
          "GL-MCDONALD-2017",
          "GL-MAGNIMS-2021"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic diagnostic plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "INT-002",
        "display": "Neurology (multiple sclerosis) consultation to confirm and classify the disease and advise on disease-modifying therapy, its monitoring, vaccination, symptom care and MRI follow-up",
        "status": "completed",
        "guideline_ids": [
          "GL-AAN-DMT-2018",
          "GL-MCDONALD-2017",
          "GL-MAGNIMS-2021"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0006"
          ],
          "synthetic_reason": "Synthetic specialist consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "INT-003",
        "display": "Screening before any disease-modifying therapy: hepatitis B surface antigen, core antibody and surface antibody; quantitative immunoglobulins; liver tests; blood count with lymphocytes; varicella and measles immunity; tuberculosis blood test; HIV and hepatitis C; JC virus antibody; and vaccines brought up to date, inactivated vaccines at least two weeks and live vaccines at least four weeks before the first dose",
        "status": "completed",
        "guideline_ids": [
          "GL-AAN-DMT-2018",
          "GL-AAN-VAX-2019",
          "GL-CDC-IMZ-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic pre-treatment plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "INT-004",
        "display": "Relapse and pseudo-relapse plan: new or worsening symptoms lasting more than 24 hours without fever or heat mean a same-day call; check for urinary infection and fever first, because infection and heat can bring back old symptoms; written card for her bag",
        "status": "completed",
        "guideline_ids": [
          "GL-AAN-DMT-2018",
          "GL-NICE-MS-2022"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic relapse plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "INT-005",
        "display": "Mobility, spasticity and falls: physical therapy evaluation for gait, strengthening, stretching, balance and a home exercise program; review of walking aids, with forearm crutches or a rollator and a scooter for long distances when she wants them; home safety review; daily stretching",
        "status": "completed",
        "guideline_ids": [
          "GL-NICE-MS-2022",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005"
          ],
          "synthetic_reason": "Synthetic mobility plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "INT-006",
        "display": "Bladder: post-void residual today, timed voiding, fluids earlier in the day, less caffeine, pelvic floor exercises, and a medicine if urgency persists; urine check for any burning, fever or sudden worsening",
        "status": "completed",
        "guideline_ids": [
          "GL-NICE-MS-2022"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bladder plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "INT-007",
        "display": "Fatigue and heat sensitivity: energy conservation and pacing with an occupational therapy review, teaching sessions placed in the morning where she chooses, cooling garments, air conditioning, cool drinks, and aerobic exercise such as pool exercise in cool water",
        "status": "completed",
        "guideline_ids": [
          "GL-NICE-MS-2022"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic fatigue and heat plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "INT-008",
        "display": "Work: a letter to her employer, with her consent, describing her functional needs (an accessible teaching room near an elevator, a chair and lectern for lectures, reserved parking near her building, and flexibility for medical appointments) without naming the diagnosis; she decides what to disclose",
        "status": "completed",
        "guideline_ids": [
          "GL-JAN-MS",
          "GL-ADA"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [
            "CLM-0005",
            "CLM-0004"
          ],
          "synthetic_reason": "Synthetic workplace accommodation plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "INT-009",
        "display": "Bone health: vitamin D3 with a recheck, calcium from food, weight-bearing exercise, fall prevention, and bone density at the preventive visit because of reduced mobility and earlier steroid courses",
        "status": "completed",
        "guideline_ids": [
          "GL-CMID-2026",
          "GL-NICE-MS-2022"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic bone health plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "INT-010",
        "display": "Mood and cognition: PHQ-9 at intake and every six months; ask about concentration and word-finding; counseling offered at any time",
        "status": "completed",
        "guideline_ids": [
          "GL-USPSTF-DEP-2023",
          "GL-NICE-MS-2022",
          "GL-CMID-2026"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic mood plan.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        }
      },
      {
        "id": "INT-011",
        "display": "On the consultant's advice: ocrelizumab 300 mg on day 1 and day 15 and then 600 mg every 6 months, after the vaccines and at least two weeks after the last inactivated dose, with premedication and observation; blood count and immunoglobulins before each dose; a re-baseline brain MRI three to six months after the first dose and then yearly; baclofen titrated to 10 mg three times a day; mirabegron with a blood pressure check at each visit",
        "status": "completed",
        "guideline_ids": [
          "GL-AAN-DMT-2018",
          "GL-OCR-LABEL",
          "GL-MAGNIMS-2021",
          "GL-NICE-MS-2022"
        ],
        "provenance": {
          "evidence_grade": "S",
          "claim_ids": [],
          "synthetic_reason": "Synthetic plan decided at the consultation.",
          "author": "The Human Record generator",
          "created": "2026-11-04T15:00:00-05:00"
        },
        "recorded_date": "2026-03-16"
      }
    ],
    "guidelines": [
      {
        "guideline_id": "GL-AAN-DMT-2018",
        "title": "Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116)",
        "publisher": "American Academy of Neurology (Neurology)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/29686116/",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-MCDONALD-2017",
        "title": "Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977)",
        "publisher": "International Panel on Diagnosis of Multiple Sclerosis (Lancet Neurology)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/29275977/",
        "version_or_year": "2017"
      },
      {
        "guideline_id": "GL-MAGNIMS-2021",
        "title": "2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157)",
        "publisher": "MAGNIMS, CMSC and NAIMS (Lancet Neurology)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/34139157/",
        "version_or_year": "2021"
      },
      {
        "guideline_id": "GL-AAN-VAX-2019",
        "title": "Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584)",
        "publisher": "American Academy of Neurology (Neurology)",
        "url": "https://pubmed.ncbi.nlm.nih.gov/31462584/",
        "version_or_year": "2019"
      },
      {
        "guideline_id": "GL-OCR-LABEL",
        "title": "OCREVUS (ocrelizumab) injection, prescribing information",
        "publisher": "U.S. National Library of Medicine, DailyMed (Genentech label)",
        "url": "https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9da42362-3bb5-4b83-b4bb-b59fd4e55f0d",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-NICE-MS-2022",
        "title": "Multiple sclerosis in adults: management (NG220)",
        "publisher": "National Institute for Health and Care Excellence",
        "url": "https://www.nice.org.uk/guidance/ng220",
        "version_or_year": "2022"
      },
      {
        "guideline_id": "GL-JAN-MS",
        "title": "Accommodation and Compliance: Multiple Sclerosis",
        "publisher": "Job Accommodation Network (U.S. Department of Labor)",
        "url": "https://askjan.org/disabilities/Multiple-Sclerosis.cfm",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-ADA",
        "title": "Introduction to the Americans with Disabilities Act",
        "publisher": "U.S. Department of Justice",
        "url": "https://www.ada.gov/topics/intro-to-ada/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-CDC-IMZ-2026",
        "title": "Adult Immunization Schedule by Age",
        "publisher": "Centers for Disease Control and Prevention",
        "url": "https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-age.html",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-DEP-2023",
        "title": "Depression and Suicide Risk in Adults: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/screening-depression-suicide-risk-adults",
        "version_or_year": "2023"
      },
      {
        "guideline_id": "GL-CMID-2026",
        "title": "CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/topthirty/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-PREV-2026",
        "title": "Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements",
        "publisher": "Aether Forge",
        "url": "https://patrickrutledge.github.io/preventative_services/",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-AB",
        "title": "USPSTF A and B Recommendations",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations",
        "version_or_year": "2026"
      },
      {
        "guideline_id": "GL-USPSTF-BRCA-2024",
        "title": "Breast Cancer: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-screening",
        "version_or_year": "2024"
      },
      {
        "guideline_id": "GL-USPSTF-CERV-2018",
        "title": "Cervical Cancer: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cervical-cancer-screening",
        "version_or_year": "2018"
      },
      {
        "guideline_id": "GL-USPSTF-CRC-2021",
        "title": "Colorectal Cancer: Screening",
        "publisher": "U.S. Preventive Services Task Force",
        "url": "https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/colorectal-cancer-screening",
        "version_or_year": "2021"
      }
    ]
  },
  "review": {
    "schema_validation": {
      "status": "not_started",
      "notes": "Run scripts/build.ps1 -Conformance."
    },
    "clinical_review": {
      "status": "not_started",
      "notes": "Awaiting clinician review; check the McDonald classification as active primary progressive disease, the ocrelizumab choice and its screening, the vaccine timing, the re-baseline MRI without gadolinium, baclofen and mirabegron, and the decision to obtain bone density at 44."
    },
    "provenance_review": {
      "status": "not_started",
      "notes": "Recent-death rule: only what was reported in her life or in obituaries and reference works: the Texas State Historical Association, the House history, the Los Angeles Times obituary, a broadcaster's profile, an encyclopedia entry, a biography site, the State Cemetery and one disability-press article. The diagnosis year and the date of disclosure are uncertain and recorded as such."
    },
    "safe_messaging_review": {
      "status": "not_started",
      "notes": "No mental health or substance claims are made; mood screening is synthetic and below the threshold for a safety assessment. Her death is recorded in one claim as history. Disability is described without pity language, and her privacy about the diagnosis is respected in the modern plan."
    }
  }
}
